Journal of Pharmaceutical Sciences

A publication of the American Pharmaceutical Association

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 59
JANUARY TO DECEMBER, 1970

Published monthly under the supervision of the Committee on Publications with the approval of the Board of Trustees

EDWARD G. FELDMANN
Editor

MARY HUDSON FERGUSON
Associate Editor

SHELLY ELLIOTT
Production Editor

L. LUAN CORRIGAN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

LINDA A. LAFONTAINE
Contributing Editor

COMMITTEE ON PUBLICATIONS

ROBERT C. JOHNSON
Chairman
WILLIAM S. APPLE
GROVER C. BOWLES, JR.
CLIFTON J. LATIOLAIS
JOHN H. NEUMANN

EDITORIAL ADVISORY BOARD

JACK COOPER
EDWARD R. GARRETT
GERHARD LEVY
W. LEWIS NOBLES
G. VICTOR ROSSI
GORDON H. SVOBODA

© Copyright 1970 by the American Pharmaceutical Association

Author Index

A

Abbs, E. T., *see* Short, P. M., 995
Abruzzo, C. W., *see* Kaplan, S. A., 358, 1569
Acel, K., and Tuckerman, M. M., assay of emetine hydrochloride injection, 1649
Ahuja, S., Spiegel, D., and Brofazi, F. R., stabilization of homatropine methylbromide—iodobismuthate complex in solution for quantitative analysis of homatropine methylbromide, 417
——Spitzer, C., and Brofazi, F. R., automated dual extraction procedure for analysis of phenmetrazine hydrochloride tablets, 1833
Albrecht, W. L., *see* Smissman, E. E., 1696
Alexander, K., *see* Kaplan, S. A., 358
Allen, G. R., Jr., *see* Floyd, M. B., 869
Allen, R. C., *see* Cammarata, A., 1496
Allwood, M. C., and Russell, A. D., influence of ionic and nonionic materials on thermally-induced ribonucleic acid degradation and leakage in *Staphylococcus aureus*, 180
Ambike, S. H., and Baxter, R. M., cytochrome P-450 and alkaloid synthesis in *Claviceps purpurea*, 1149
Anderson, C. A., *see* Balazs, M. K., 563
Anfinsen, J. R., *see* Karkhanis, P. P., 535
Ansel, H. C., and Cabre, G. E., influence of dimethyl sulfoxide on the hemolytic activity of antimicrobial preservatives I, 478
——*see* Norred, W. P., 618
Aparajithan, K., *see* Sam, J., 59
Apelian, H. M., *see* Nessel, R. J., 254
Appelt, G. D., *see* Ferguson, G. G., 1584
Arrigoni, E., *see* Benzi, G., 556, 1198
Ascione, P. P., and Chrekian, G. P., separation and determination of anhydrotetracycline, 4-epianhydrotetracycline, tetracycline, and 4-epitetracycline in a tetracyline mixture, 1480
Augsburger, L. L., *see* Vora, K. R. M., 1012
Augustine, M. A., and Swarbrick, J., effect of lipid polarity and cell design on the *in vitro* transport of salicylic acid, 314
Avdovich, H. W., Bowron, M., and Lodge, B. A., NMR analysis of mestranol bulk drug, 1821
——Hanbury, P., and Lodge, B. A., NMR analysis of synthetic corticosteriods o the 1,4-dien-3-one type, 1164
Azaz, E., *see* Donbrow, M., 1427

B

Bahal, C. K., *see* Poole, J. W., 1265
Bahal, S. M., *see* Hem, S. L., 317, 376
——*see* Kostenbauder, H. B., 1047
Bailey, A., *see* Lantz, R. J., 1174
Balazs, M. K., Anderson, C. A., Iwamoto, R. H., and Lim, P., synthesis of 4-{p-[(2-chloroethyl) - (2 - hydroxyethyl)amino]-phenyl}butyric acid and its behavior in the 4-(4-nitrobenzyl)pyridine assay procedure, 563
Ballard, B. E., and Menczel, E., subcutaneous absorption kinetics of benzyl alcohol II, 714
Banerjee, S., Mukherjee, A. K., and Halder, A. K., pentaerythritol tetranitrate sustained-release tablets: relation of *in vitro* release of the drug to blood pressure changes after administration to anesthetized cats, 273
Banker, G. S., *see* Fites, A. L., 610
——*see* Fonner, D. E., Jr., 1587
——*see* Goodman, H., 1131
——*see* Heyd, A., 947
——*see* Jablon, P. A., 1143
——*see* Kildsig, D. O., 1634
——*see* Rhodes, C. T., 1578, 1581
Barber, M. A., *see* Kapadia, A. J., 1476
Bardos, T. J., *see* Navada, C. K., 1079
Barfknecht, C. F., Miles, J. M., and Leseney, J. L., 1-(3,4-dimethoxyphenyl)-2-propanol effect on conditioned avoidance response in the rat, 1842
Barletta, M. A., and Ward, C. O., spectrophotometric analysis of acetylcholine levels in plasma, 879
——*see* Ward, C. O., 1661
Barnett, P. A., *see* Puffer, H. W., 848
Barr, F. S., Moore, G. W., and Gragg, B. J., potentiating effect of organomercurials on bisphenols, 262
Barr, M., *see* Randinitis, E. J., 806, 813
Barr, W. H., and Riegelman, S., intestinal drug absorption and metabolism I: comparison of methods and models to study physiological factors of *in vitro* and *in vivo* intestinal absorption, 154
——and Riegelman, S., intestinal drug absorption and metabolism II: kinetic aspects of intestinal glucuronide conjugation, 164
Barrette, J. P., *see* Malaiyandi, M., 568
Barry, H., III., *see* Marcus, F., 1616
Batchelder, M., *see* Tarlin, H. I., 1328
Bates, T. R., *see* Johns, W. H., 329, 788
Baxter, R. M., *see* Ambike, S. H., 1149
——*see* Murty, B. S. R., 1010, 1042
Becker, C. H., *see* Hamid, I. S., 511
Benedict, R. G., *see* Gaylord, M. C., 1420
Benet, L. Z., *see* Rowland, M., 364
——*see* Turner, R. H., 590
Benney, T. L., *see* Russo, E. J., 883
Bentley, D. L., statistical techniques in predicting thermal stability, 464
Benzi, G., Bermudez, E., and Arrigoni, E., action of antibiotics on respiratory tract I: ampicillin, 556
——Berté, F., Bermudez, E., and Arrigoni, E., action on antibiotics on respiratory tract II: dicloxacillin, 1198
Berger, J., *see* Newmark, H. L., 1246, 1249
Bermudez, E., *see* Benzi, G., 556, 1198
Bernardo, P. D., *see* Mehta, S. C., 638
Berté, F., *see* Benzi, G., 1198
Beyer, W. F., and Smith, E. W., construction and operation of an automated dispensing analyzer for the assay of individual tablets, 248
Bhatti, M. C., Shaw, S. M., Lewis, R. E., and Christian, J. E., comparison of whole-body liquid scintillometry, radiography, and clinical chemical tests in the evaluation of the effect of chronic corticoid dosing on calcium in beagles, 368
Bickel, M. H., *see* Weder, H. J., 1563
Bighley, L. D., *see* Lach, J. L., 1261
Bikhazi, A. B., and Higuchi, W. I., interfacial barrier limited interphase transport of cholesterol in the aqueous polysorbate 80–hexadecane system, 744
Biles, J. A., *see* Plakogiannis, F. M., 197
Billman, J. H., and Roehrig, G. R., 1,3,2-dioxaphosphorinane 2-oxides IV: preparation of some 2-substituted-5-carbomethoxy-5-methyl-1,3,2-dioxaphosphorinane 2-oxides as potential antitumor agents, 861
——and Schmidgall, R. L., preparation and antitumor activity of some Schiff bases of 2′ - amino - 4′,5′ - dichlorobenzenesulfonanilide and 2′-amino-*p*-toluenesulfonanilide, 1191
Birner, J., determination of phenoxymethyl penicilloic acid and phenoxyethyl penicilloic acid in urine in the presence of the parent penicillins, 757
Bischoff, K. B., Dedrick, R. L., and Zaharko, D. S., preliminary model for methotrexate pharmacokinetics, 149
Bishara, R. H., and Jakovljevic, I. M., thin-layer chromatographic method for the determination of flurandrenolone acetonide and some closely related foreign steroids, 124
Blake, M. I., *see* Carlstedt, B. C., 1456
——*see* Hunt, J., 683
——*see* Mohammed, K., 419
Blake, P. H., *see* Nelson, W. L., 1676
Blanton, C. D., Jr., *see* Talati, S. M., 491
Block, J. H., Nunes, M. A., and Muhlhauser, R. O., alternatives to the *National Formulary* procedure for detecting nitrobenzene in benzaldehyde, 1008
Blodinger, J., *see* Nessel, R. J., 254
Bloor, J. R., Morrison, J. C., and Rhodes, C. T., effect of pH on the micellar properties of a nonionic surfactant, 387
Bollinger, J. N., metabolic fate of mineral oil adjuvants using ^{14}C-labeled tracers I: mineral oil, 1084
——metabolic fate of mineral oil adjuvants using ^{14}C-labeled tracers II: mannide monooleate, 1088
Bond, H. W., *see* Worthen, L. R., 1185
Born, G. S., *see* Ebert, W. R., 1409
——*see* Rowles, S. G., 257
Borodkin, S., and Yunker, M. H., interaction of amine drugs with a polycarboxylic acid ion-exchange resin, 481
Borzelleca, J. F., *see* Lowenthal, W., 1353
Bottari, F., Mannelli, M., and Saettone, M. F., thermal dissociation of sulfonylureas: dissociation of tolbutamide in a series of aliphatic alcohols and in polyethylene glycol 400, 1663
Bowman, F. W., *see* Calhoun, M. P., 1022
Bowron, M., *see* Avdovich, H. W., 1821
Boyce, G. M., *see* Foye, W. O., 1348
Boyd, E. M., and Muis, L. F., acute oral toxicity of dimethoate in albino rats fed a protein-deficient diet, 1098
Boyd, R. F., and Judis, J., factors affecting the synthesis of penicillinase by *Staphylococcus aureus*, 81
Brady, L. R., *see* Gaylord, M. C., 1420
Breon, T. L., and Paruta, A. N., solubility profiles for several barbiturates in hydroalcoholic mixtures, 1306
Breslow, D. M., *see* Hamor, G. H., 1752
Breunig, H. L., *see* Comer, J. P., 210
——*see* Sampson, C. B., 1653
Broadlick, D. E., *see* Comer, J. P., 210
——*see* Sampson, C. B., 1653
Brofazi, F. R., *see* Ahuja, S., 417, 1833
Brommet, M. R., *see* Dijkhuis, I. C., 558
Brown, R. G., *see* Saenz, R. V., 942
Bruce, R. B., *see* Maynard, W. R., 1346
Bruno, Q. J., *see* Henderson, N. L., 1336
Buck, J. R., *see* Fonner, D. E., Jr., 1587
Buckley, J. P., *see* Geyer, H. M., III, 964
——*see* Kelliher, G. J., 1276
Buehler, J. D., *see* Smith, W. E., 776
Bunch, J. L., *see* Eickholt, T. H., 1518
Burger, A., *see* Hankins, W., 342
Burke, D. H., and Mann, D. E., Jr., influence of several autonomic drugs on sodium nitroprusside- and oxotremorine-induced hypothermia in immature and mature mice, 1814
Burkman, A. M., *see* Van Tyle, W. K., 1757
Bush, I. M., *see* Dravnieks, A., 495

C

Cabre, G. E., *see* Ansel, H. C., 478
Cadwallader, D. E., and Phillips, J. R., behavior of erythrocytes in various solvent systems VI: water–tetramethylurea, 1234
——*see* Madan, D., 1362
——*see* Ullah, I., 979

Caldes, G., *see* Prescott, B., 101
Caldwell, H. C., Rednick, A. B., Scott, G. C., Yakatan, G. J., and Ziv, D., latentiation of dihydrostreptomycin by pamoate formation, 1689
Calhoun, M. P., White, M., and Bowman, F. W., sterility testing of insulin by membrane filtration: a collaborative study, 1022
Camerman, A., Jensen, L. H., Cochran, T. G., and Huitric, A. C., absolute configuration of (+)-*trans*-2-*o*-tolylcyclohexanol by X-ray crystallography, 1675
Cammarata, A., Allen, R. C., Seydel, J. K., and Wempe, E., cautions regarding the physical interpretation of statistically based structure–activity relationships, 1496
Cannon, J. G., *see* Vavrek, R. J., 823
Cardoni, A., *see* Notari, R. E., 28
Carlstedt, B. C., Crespi, H. L., Blake, M. I., and Katz, J. J., biosynthesis of deuterated benzylpenicillins I: solvent deuterium oxide participation, 1456
Carney, J. F., *see* Krol, G. J., 835, 1483
Carroll, F. I., and Wall, M. E., *N*-substituted aminoethanethiols and *N*-substituted aminoethanethiol *S*-sulfonic acids as radioprotective agents, 1350
Carstensen, J. T., kinetic salt effect in pharmaceutical investigations, 1140
——Koff, A., Johnson, J. B., and Rubin, S. H., tablet-to-tablet variation of drug content of sugar-coated tablets containing drug in the sugar coat, 553
——and Su, K. S. E., sedimentation kinetics of flocculated suspensions I: initial sedimentation region, 666
——and Su, K. S. E., sedimentation kinetics of flocculated suspensions II: sedimentation below the critical height, 671
——*see* Newmark, H. L., 1249
Chawla, A. S., *see* Singh, H., 1179
Chen, C.-H., Soine, T. O., and Lee, K. H., total synthesis of (+)-bisnorargemonine, 1529
——*see* Chiang, H.-C., 266
Chen, Y. Y., ethylene oxide penetration of the silicone coating used as a lubricant on disposable syringe rubber plunger tips and hypodermic needles, 717
Cheng, C. C., *see* Zee-Cheng, K. Y., 1630
Chiang, H.-C., and Chen, C.-H., polyamide–silica gel layer chromatography of yellow food dyes, 266
Chin, M. L., *see* Notari, R. E., 28
Chin, T. F., *see* Chung, P. H., 1300
——*see* McCallister, J. D., 1286
——*see* Wu, W. H., 1122, 1234
Chiou, C. Y., *see* Long, J. P., 133
Chiou, W. L., and Riegelman S., oral absorption of griseofulvin in dogs: increased absorption *via* solid dispersion in polyethylene glycol 6000, 937
——and Smith, L. D., adsorption of organic compounds by commercial filter papers and its implication on quantitative–qualitative chemical analysis, 843
Chitharanjan, D., *see* Harmon, R. E., 1031
Chmielewicz, Z. F., *see* Navada, C. K., 1079
Cho, M. J., and Pernarowski, M., application of absorbance ratios to analysis of pharmaceuticals VI: analysis of binary mixture using a reference spectrum, 1333
Cho, Y. J., *see* Foye, W. O., 114
Chong, J. E., *see* Warren, R. J., 109
Chou, S. C., *see* Conklin K. A., 704
Chrekian, G. P., *see* Ascione, P. P., 1480
Christian, J. E., *see* Bhatti, M. C., 368
——*see* Ebert, W. R., 1409
——*see* Huff, J. E., 126
——*see* Jarboe, R. H., 1019
——*see* Morris, C. H., 270, 325
——*see* Rowles S. G., 257
——*see* Wolfangel, R. G., 468
Christian, S. T., *see* Magarian, E. O., 1028
Chu, B. L. W., and Mika, E. S., use of tetraphenylethylene in quantitative GLC of hyoscyamine and scopolamine, 1508
Chu, D., and Windheuser, J. J., interference of polycarboxylic acids in the determination of ester degradation by the hydroxamic acid procedure, 130
Chu, I., *see* Yung, D. K., 1405
Chung, P. H., Chin, T. F., and Lach, J. L., kinetics of the hydrolysis of pilocarpine in aqueous solution, 1300
Chupp, J. P., lidocaine: evidence for the *trans*-configuration, 1524
Clark, M. L., *see* Kaul, P. N., 1745
Clemson, H. C., Magarian, E. O., and Reinhard, J. F., synthesis and anticonvulsant properties of some derivatives of *N*-methyl-2-phenylsuccinimide II, 1137
——*see* Magarian, E. O., 1028
Coats, E., *see* Hansch, C., 731
Cochran, T. G., *see* Camerman, A., 1675
Cohen, J. L., and Connors, K. A., stability and structure of some organic molecular complexes in aqueous solution, 1271
Colaizzi, J. L., *see* Marcus, F., 1616
Cole, H. F., and Wolf, H. H., laboratory evaluation of aggressive behavior of the grasshopper mouse (*Onychomys*), 969
Comer, J. P., Bruenig, H. L., Broadlick, D. E., and Sampson, C. B., estimation of mean potency and content uniformity of tablets: a new approach, 210
——*see* Sampson, C. B., 1653
Conklin, K. A., Heu, P., and Chou, S. C., quinine—effect on *Tetrahymena pyriformis* II: comparative activity of the stereoisomers, quinidine and quinine, 704
Connors, K. A., *see* Cohen, J. L., 1271
Contractor, A. M., Richman, M. D., and Shangraw, R. F., factors affecting dose variation in meter valves, 1488
Conway, M. W., *see* Kaul, P. N., 1745
Corder, C. D., Jr., *see* Lowenthal, W., 1353
Cotler, S., *see* Kaplan, S. A., 358, 1569
Crane, F. A., *see* Solomon, M. J., 1670, 1680
Craven, B. M., and Gartland, G. L., molecular association of barbital and caffeine in 2:1 crystalline complex, 1666
Crespi, H. L., *see* Carlstedt, B. C., 1456
Crouthamel, W., Doluisio, J. T., Johnson, R. E., and Diamond, L., effect of mesenteric blood flow on intestinal drug absorption, 878
——*see* Doluisio, J. T., 72
Cucinell, S. A., and Perl, W., application of clearance and volume of distribution to the plateau principle of drugs, 1423
Cullen, L. F., Packman, D. L., and Papariello, G. J., automated fluorometric procedure for unit dose analysis of digitoxin and digoxin in tablet formulations, 697
——and Papariello, G. J., sampling and analysis of oxygen in the void volume of ampuls and vials, 94
Cummings, B., *see* Rao, K. V., 1501

D

Danna, L. J., *see* Eickholt, T. H., 1518
Darling, C. M., and Rose, E. K., new compounds: demethylated methocarbamol, 1043
Das Gupta, V., and Reed, J. B., Jr., first pKa values of some acid-base indicators, 1683
Data, J. B., *see* Jarboe, R. H., 1019
Davis, C. S., *see* Wright, G. C., 105
Davis, S. S., Warburton, B., and Dippy, J. E., chemical balance as a rheometer for biological fluids, 1764
——*see* Higuchi, T., 1376
Davis, W. W., Pfeiffer, R. R., and Quay, J. F., normal and promoted gastrointestinal absorption of water-soluble substances I: induced rapidly reversible hyperabsorptive state in the canine fundic stomach pouch, 960
Dawn, H., Pitman, I. H., and Higuchi, T., covalent addition of *N*-chlorosaccharin to cyclohexene, 429
——Pitman, I. H., Higuchi, T., and Young, S., *N*-chlorosaccharin as a possible chlorinating reagent: structure, chlorine potential, and stability in water and organic solvents, 955
Dedrick, R. L., *see* Bischoff, K. B., 149
De Fabrizio, F., spectrophotometric determination of diphenhydramine hydrochloride in an antiallergic cream, 1470
DeGraw, J. I., *see* Johnson, H. L., 278
Delgado, J. N., *see* Szenz, R. V., 942
Demarco, P. V., *see* Thakkar, A. L., 281
De Ritter, E., Magid, L., Osadca, M., and Rubin, S. H., effect of silica gel on stability and biological availability of ascorbic acid, 229
de Silva, J. A. F., Munno, N., and Strojny, N., absorptiometric, polarographic, and gas chromatographic assays for the determination of *N*-1-substituted nitroimidazoles in blood and urine, 201
Devani, M. B., and Shishoo, C. J., differential nonaqueous titration of isoniazid and sodium *p*-aminosalicylate mixture, 90
——*see* Shishoo, C. J., 92
Diamond, L., *see* Crouthamel, W., 878
DiCarlo, F. J., and Viau, J. P., prazepam metabolites in dog urine, 322
Digenis, G. A., Thorson, R. E., and Konyalian, A., cholesterol bios nthesis and lipid biochemistry in the scole : of *Echinococcus granulosus*, 676
Dijkhuis, I. C., and Brommet, M. R., determination of epitetracycline and chlortetracycline in tetracycline by quantitative thin-layer chromatography, 558
DiPasquale, G., Rassaert, C. L., and McDougall, E., modified granuloma pouch procedure for the evaluation of topically applied anti-inflammatory steroids, 267
Dippy, J. E., *see* Davis, S. S., 1764
Discher, C. A., *see* Shin, C. T., 297
Dittert, L. W., *see* Doluisio, J. T., 72
——*see* Rattie, E. S., 1738
Dizon, C. M., *see* Levine, R. R., 1845
Dodson, G. J., *see* Irwin, G. M., 547
Doluisio, J. T., Crouthamel, W. G., Tan, G. H., Swintosky, J. V., and Dittert, L. W., drug absorption III: effect of membrane storage on the kinetics of drug absorption, 72
——*see* Crouthamel, W., 878
Donbrow, M., Azaz, E., and Hamburger, R., application of molecular sieve technique in solubilization studies of benzoic acid in solutions of cetomacrogol 1000, 1427
Douglas, J. F., and Stockage, J. A., gas chromatographic determination of *N*-γ-phenylpropyl-*N*-benzyloxy acetamide (W-1372) in blood, 850
——Stockage, J. A., and Smith, N. B., gas chromatographic determination of chlorphenesin in plasma, 107
——*see* Edelson, J., 680
Draper J. R., *see* Goodhart, F. W., 540
Dravni ks, A., Krotoszynski, B. K., Keith, L., and Bush, I. M., odor threshold and gas-chromatographic assays of vaginal odors: changes with nitrofurazone treatment, 495
Dresback, D. S., and Gallelli, J. F., quantitative analysis and stability of 5(or 4)-[3,3 - bis(2 - chloroethyl) - 1 - triazeno]-imidazole-4(or 5)-carboxamide in acidic aqueous solutions, 1829

E

Ebert, W. R., Morris, R. W., Rowles, S. G., Russell, H. T., Born, G. S., and Christian, J. E., *in vivo* evaluation of absorption and excretion of pentylenetetrazol-10-^{14}C from sustained-release and nonsustained-release tablets, 1409
Ecanow, B., and Takruri, H., flocculation theory and polysorbate 80–sulfaguanidine suspensions, 1848
Edelson, J., Douglas, J. F., and Ludwig, B. J., metabolic fate of *n*-γ-phenylpropyl-*n*-benzyloxy acetamide (W-1372) in rats, dogs, and monkeys, 680
Eickholt, T. H., Danna, L. J., Verzwyvelt, L. J., Waguespack, G. P., Bunch, J. L., and Winslow, D. D., comparison of effects of 1,8-dihydroxyanthraquinone and 1,5-dihydroxyanthraquinone on different segments of rabbit gastrointestinal tract, 1518
El-Dakhakhny, M., some coumarin constituents of *Prunus mahaleb* L. fruit kernels V, 551
El-Kiey, M. A., *see* Karawya, M. S., 1025
ElMasry, A. H., and Gisvold, O., 19-norsteroids of unnatural configuration from ergosterol, 449
Erb, R. J., *see* Smolen, V. F., 1093
Eriksen, S. P., *see* Robinson, J. R., 1796
Estevez, V., *see* Ho, B. T., 1780
Evert, C. F., and Randall, M. J., formulation and computation of compartment models, 403

F

Farhan, F. M., and Makhani, M., spectrographic determination of traces of cobalt in vitamin B_{12} preparations, 1200

Farnsworth, N. R., *see* Segelman, A. B., 726
Fayez, M. B. E., *see* Kapadia, G. J., 1699
Feldman, J. A., and Robb, B. J., colorimetric determination of atropine, homatropine, scopolamine, and their derivatives by the ferric hydroxamate method, 1646
Feldman, S., Salvino, M., and Gibaldi, M., physiologic surface-active agents and drug absorption VII: effect of sodium deoxycholate on phenol red absorption in the rat, 705
——*see* Gibaldi, M., 579
Fell, J. T., and Newton, J. M., determination of tablet strength by the diametral-compression test, 688
Felmeister, A., and Tolat, S. V., phospholipid spherules as a model to assess photosensitizing properties of drugs, 856
——*see* Kamel, A. M., 1807
Ferguson, G. G., Heim, H. C., and Appelt, G. D., selected pharmacological studies of a series of substituted imidazo(4,5-*d*)-pyridazines, 1584
Fiegenschue, B., *see* Singh, J. M., 1020
Finholt, P., *see* Solvang, S., 49
Fisch, G. W., *see* Hamor, G. H., 1752
Fites, A. L., Banker, G. S., and Smolen, V. F., controlled drug release through polymeric films, 610
Floss, H. G., *see* Robbers, J. E., 702
Floyd, M. B., and Allen, G. R. Jr., cyclic analog of ethacrynic acid, 869
Flynn, G. L., and Lamb, D. J., factors influencing solvolysis of corticosteroid-21-phosphate esters, 1433
Fonner, D. E., Jr., Buck, J. R., and Banker, G. S., mathematical optimization techniques in drug product design and process analysis, 1587
Fontani, F., *see* Setnikar, I., 1319
Forlano, A. J., Jarowski, C. I., Hammer, H. F., and Merritt, E. C., sterically hindered esters of vitamin A II: vitamin A α,α-dimethylpalmitate, 121
Fowler, K. C., *see* Mathison, I. W., 998
Fowler, W. L., *see* Mathison, I. W., 998
Foxx, M., *see* Gruber, M., 830
Foye, W. O., Cho, Y. J., and Oh, K. H., antiradiation compounds XIII: 1-(dithioacetic acid)-pyridinium betaines, 114
——Mickles, J., and Boyce, G. M., antiradiation compounds XIV: dithiocarbamates of aminothiophenes, 1348
——and Speranza, J. P., *N*-acyl derivatives of bis-(4-aminophenyl) disulfide and its thiolsulfinate, 259
Franchetti, P., Grifantini, M., and Stein, M. L., structure–activity relation in organophosphorus-inhibited acetylcholinesterase reactivators III: methiodides of hydroxyimino derivatives of pyridylethanes, 710
French, W. N., *see* Watson, J. R., 391
Friberg, S., and Mandell, L., influence of phase equilibria on properties of emulsions, 1001
Fujimoto, J. M., *see* Hakim, R., 1783

G

Gainer, F. E., and Wesselman, H. J., GLC of mycophenolic acid and related compounds, 1157
Gallelli, J. F., *see* Dresback, D. S., 1829
Gallo, G. G., *see* Pasqualucci, C. R., 685
Garden, J., II, *see* Tometsko, A. M., 1655
Garg, H. G., and Sharma, R. A., new compounds: potential antineoplastics VI: 2,4-diamino - 6 - hydroxy - 5 - arylazopyrimidines and 1,3-dimethyl-5-arylhydrazonoalloxans, 1691
——and Sharma, R. A., potential antineoplastics II: 1-thiocarbamoyl-3-methyl-4-arylhydrazono - 2 - pyrazolin - 5 - ones, 2-amino-4-phenyl-5-arylazothiazoles, and *N* - phenyl - *N'* - 2(4 - phenyl - 5 - arylazothiazolyl)thiocarbamides, 348
——and Singh, P. P., new compounds: potential antidiabetics IV: 1-(2,4-dinitrophenyl)-3,5-diphenyl - 4 - arylazopyrazoles and 1-carbamoyl-3,5-diphenyl-4-arylazopyrazoles, 876
Garrett, E. R., Heman-Ackah, S. M., and Perry, G. L., kinetics and mechanisms of action of drugs on microorganisms XI: effect of erythromycin and its supposed antagonism with lincomycin on the microbial growth of *Escherichia coli*, 1448
——and Weber, D. J., metal complexes of thiouracils I: stability constants by potentiometric titration studies and structures of complexes, 1383
——*see* Mielck, J. B., 760
Garson, L. R., *see* Quintana, R. P., 1503
Gartland, G. L., *see* Craven, B. M., 1666
Gaylord, M. C., Benedict, R. G., Hatfield, G. M., and Brady, L. R., isolation of diphenyl-substituted tetronic acids from cultures of *Paxillus atrotomentosus*, 1420
Geller, B. L., *see* Harmon, R. E., 1031
Gessner, T., and Hamada, N., identification of *p*-nitrophenyl glucoside as a urinary metabolite, 1528
Geyer, H. M. III, Watzman, N., and Buckley, J. P., effects of a tranquilizer and two antidepressants on learned and unlearned behaviors, 964
Ghanem, A. H., Higuchi, W. I., and Simonelli, A. P., interfacial barriers in interphase transport II: influence of additives upon the transport of diethylphthalate across the hexadecane–gelatin–water interface, 232
——Higuchi, W. I., and Simonelli, A. P., interfacial barriers in interphase transport III: transport of cholesterol and other organic solutes into hexadecane–gelatin–water matrices, 659
Ghourab, M. G., *see* Karawya, M. S., 1331
Giaquinto, A. R., *see* Lindstrom, R. E., 1625
Gibaldi, M., and Feldman, S., mechanisms of surfactant effects on drug absorption, 579
——and Weintraub, H., quantitative correlation of absorption and *in vitro* dissolution kinetics of aspirin from several dosage forms, 725
——*see* Feldman, S., 705
——*see* Weintraub, H., 1792
Gibbs, I. S., and Tuckerman, M. M., optimal ferric hydroxamate method for determination of intact pilocarpine, 395
Gibson, R. D., and Tingstad, J. E., formulation of a morphine implantation pellet suitable for tolerance–physical dependence studies in mice, 426
Gilbert, I. H., *see* Quintana, R. P., 1503
Gisvold, O., *see* ElMasry, A. H., 449
——*see* Ishaq, K. S., 412
Goldstein, F. J., and Packman, E. W., evaluation of an improved Heidelberg technetry capsule for the study of antacids, 425
Goodhart, F. W., Draper, J. R., and Ninger, F. C., utilization of the solids processor for preparation of tablet granulations, 540
Goodman, H., and Banker, G. S., molecular-scale drug entrapment as a precise method of controlled drug release I: entrapment of cationic drugs by polymeric flucculation, 1131
Goras, J. T., Knight, J. B., Iwamoto, R. H., and Lim, P., gas-liquid chromatographic determination of melphalan, 561
Gordon, P., *see* LeVan, H., 1178
Gorodischer, R., *see* Jusko, W. J., 473
Gorski, R. J., *see* Sennello, L. T., 1530
Gouda, M. W., Ismail, A. A., and Motawi, M. M., micellar solubilization of barbiturates II: solubilities of certain barbiturates in polyoxyethylene stearates of varying hydrophilic chain length, 1402
——*see* Ismail, A. A., 220
Govan, H. K., *see* Mollica, J. A., 1770
Grady, L. T., and Zimmerer, R. O., USP collaborative study of the assay of atropine and scopolamine dosage forms, 1324
——*see* Zimmerer, R. O., Jr., 87
Gragg, B. J., *see* Barr, F. S., 262
Graham, R. E., Williams, P. A., and Kenner, C. T., acetonitrile–diatomaceous earth column for corticosteroids, 1472
——Williams, P. A., and Kenner, C. T., detection of decomposition and analytical interferences in pharmaceutical preparations containing corticosteroids, 1152
Green, D. E., Martin, A. R., and White, A. I. substituted tetralins II: preparation of 2-amino - 4 - carbamyl - 6 - methoxy - 4-methyltetralin, 526
Grifantini, M., *see* Franchetti, P., 710
Gringauz, A., certain disubstituted *o*-aminoacetoxy- and propoxybenzoic and cinnamic acids and their *tert*-butyl esters, 422
Groff, W. A., *see* Sidell, F. R., 793
Gruber, M., Klein, R., and Foxx, M., chemical standardization and quality assurance of whole crude coal tar USP utilizing GLC procedures, 830
Guillory, J. K., *see* Lin, H. O., 972
Gupta, P. K., *see* Shipchandler, M., 67
Gupta, S. K., *see* Harmon, R. E., 576, 724, 871, 1031, 1356, 1694
Gustafson, J. H., *see* Oesterling, T. O., 1612
Guttman, D. E., *see* Hayton, W. L., 575
——*see* Meyer, M. C., 33, 39
Gyanchandani, N. D., McGilveray, I. J., and Hughes, D. W., improved thin-layer chromatographic identification of tetracyclines and their degradation products: application to an epimerization study, 224

H

Hakim, R., and Fujimoto, J. M., extraction of morphine enhanced by addition of *N*-methyl - 3 - piperidyl - (*N'N'*) - diphenylcarbamate, 1783
Halder, A. K., *see* Banerjee, S., 273
Halliday, R. P., *see* Wright, G. C., 105
Hamada, N., *see* Gessner, T., 1528
Hamburger, R., *see* Donbrow, M., 1427
Hamid, I. S., and Becker, C. H., release study of sulfaethylthiadiazole (SETD) from a tablet dosage form prepared from spray-congealed formulations of SETD and wax, 511
Hammarlund, E. R., *see* Wang, E. S. N., 1559
Hammer, H. F., *see* Forlano, A. J., 121
Hamor, G. H., Breslow, D. M., and Fisch, G. W., benzyloxyamines as possible inhibitors of histamine biosynthesis, 1752
——and Hudaverdi, A., 4-thiazolylmethoxyureas as potential anticancer agents, 276
Hanbury, P., *see* Avdovich, H. W., 1164
Hanka, L. J., *see* Harmon, R. E., 576, 1356, 1694
Hankins, W., and Burger, A., pyrrolidine-substituted nicotine analogs: synthesis and pharmacology, 342
Hansch, C., and Coats, E., α-chymotrypsin: a case study of substituent constants and regression analysis in enzymic structure–activity relationships, 731
Hansen, J. L., *see* Harmon, R. E., 724, 1356
Hansen, W. G., *see* Morris, C. H., 270, 325
Harder, S. W., Zuck, D. A., and Wood, J. A., characterization of tablet surfaces by their critical surface-tension values, 1787
Hargreaves, G. W., *see* Talati, S. M., 491
Harmon, R. E., Geller, B. L., Gupta, S. K., Herbert, M. H., and Chitharanjan, D., antimalarial properties of a variety of substituted *p*-sulfamoylphenylazo compounds, 1031
——Gupta, S. K., and Hansen, J. L., cytotoxic activity of imidazole derivatives, 724
——Gupta, S. K., Hansen, J. L. and Hanka, L. J., preparation and biological activity of substituted 1,3-distyryl-4,6-dinitrobenzenes, 1356
——Gupta, S. K., Johnson, J., Stanley, F., Jr., and Hanka, L. J., antimetabolite activity by some *N,N*-dialkylamino-1,2,3-triazoles and α-diazoamidines, 1694
——Jensen, B. L., Gupta, S. K., and Hanka, L. J., synthesis and antibacterial activity of 1-styryl-3,4-dihydroisoquinolines, 576
——Meulman, P. A., and Gupta, S. K., preparation and anticancer activity of 2-diethylaminoethyl-*cis*- and -*trans*-methylcyclohexanecarboxylates, 871
Harrell, W. B., Mannich bases from 1,2-diphenylindolizine: ephedrine and methamphetamine as amine components, 275
——Kuang, S. W., and O'Dell, C., new compounds: Mannich bases from 1,2-diphenylindolizine—*N*-substituted cyclohexylaminomethyl derivatives, 721
Harris, C., *see* Plakogiannis, F. M., 197
Hart, P. A., *see* Perrin, J. H., 431
Harwood, R. J., *see* Hem, S. L., 376
Hatfield, G. M., *see* Gaylord, M. C., 1420

Hayton, W. L., Guttman, D. E., and Levy, G., enhancement of steroid absorption by dialkylamides, 575
Hazlett, J. R., and Kildsig, D. O., factors affecting a fluorometric assay of folic acid, 570
Heim, H. C., *see* Ferguson, G. G., 1584
Hem, S. L., Russo, E. J., Bahal, S. M., and Levi, R. S., effect of pH of precipitation on antacid properties of hydrous aluminum oxide, 317
——Russo, E. J., Harwood, R. J., Tejani, B. H., Bahal, S. M., and Levi, R. S., kinetics of hydrous aluminum oxide conversion in mixtures of amorphous alumina gels of various acid reactivities, 376
Heman-Ackah, S. M., *see* Garrett, E. R., 1448
Hemsworth, B. A., and West, G. B., anticholinesterase activity of some degradation products of physostigmine, 118
Henderson, N. L., and Bruno, A. J., lactose USP (beadlets) and dextrose (PAF 2011): two new agents for direct compression, 1336
Herbert, M. H., *see* Harmon, R. E., 1031
Herzog, K. A., and Swarbrick, J., drug permeation through thin model membranes I: development of a polymeric model biomembrane, 1759
Heu, P., *see* Conklin, K. A., 704
Heyd, A., macromolecular dissolution: temperature effects on polymer–drug preparation, 1526
——and Kanig, J. L., improved self-programming automated tablet-coating system, 1171
——Kildsig, D. O., and Banker, G. S., dissolution of macromolecules II: dissolution of an ethylene–maleic acid copolymer, 947
Higgins, J. W., *see* Weber, D. J., 1819
Higuchi, T., and Davis, S. S., thermodynamic analysis of structure–activity relationships of drugs: prediction of optimal structure, 1376
——and Kristiansen, H., binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies, 1601
——*see* Dawn, H., 429
——*see* Dawn, H. S., 955
——*see* Kristiansen, H., 1103
——*see* Sandmann, B., 427
Higuchi, W. I., *see* Bikhazi, A. B., 744
——*see* Ghanem, A. H., 232, 659
——*see* Ho, N. F. H., 1125
——*see* Mehta, S. C., 638
——*see* Mufson, D., 601
——*see* Roseman, T. J., 353
——*see* Simonelli, A. P., 633
——*see* Suzuki, A., 644, 651
Hirschorn, J. O., *see* Kornblum, S. S., 606
Ho, B. T., Estevez, V., and McIsaac, W. M., effect of vehicles on metabolism of serotonin and imipramine, 1780
——Li, K. C., Walker, K. E., Tansey, L. W., Kralik, P. M., and McIsaac, W. M., inhibitors of monamine oxidase VI: effects of substitution on inhibitory activity of 6(or 8)-substituted β-carbolines, 1445
——Noel, M. B., and McIsaac, W. M., hydroxyindole-*o*-methyltransferase IV: inhibitory activities of some *N*-acrylyltryptamines and *N*-crotonyltryptamines, 573
Ho, N. F. H., Suzuki, A., and Higuchi, W. I., electrostatic interaction of oil droplets with adsorbed surface-active ions in dilute electrolyte solutions, 1125
——*see* Suzuki, A., 644, 651
Holck, H. G. O., Lish, P. M., Sjogren, D. W., Westerfeld, W. W., and Malone, M. H., effects of disulfiram on growth, longevity, and reproduction of the albino rat, 1267
Hom, F. S., and Miskel, J. J., oral dosage form design and its influence on dissolution rates for a series of drugs, 827
Hong, C. I., Piantadosi, C., and Irvin, J. L., potential anticancer agents VI: 5-substituted pyrimidine-6-carboxaldehydes, 1637
Howlett, M. R., *see* Walton, V. C., 1160
Hsu, S. Y., *see* Huang, C. L., 772
Huang, C. L., Mir, G. M., and Yeh, J. Z., distribution, excretion, and metabolism of ^{14}C-labeled quaternary ammonium salt of perphenazine in rats, 976
——Yeh, J. A., and Hsu, S. Y., distribution, excretion, and metabolism of ^{14}C-labeled quaternary ammonium salt of mepazine and promethazine in rats, 772
——Yeh, J. Z., and Muni, I. A., comparative distribution, excretion, and metabolism of ^{14}C-labeled quaternary ammonium compounds of promazine, chlorpromazine, and triflupromazine, 1114
Hudanick, J., gas chromtographic determination of glycerol guaiacolate in pharmaceutical preparations, 238
Hudaverdi, A., *see* Hamor, G. H., 276
Huff, J. E., Shaw, S. M., and Christian, J. E., effect of acute and chronic stress on amobarbital metabolism in the rat, 126
Huffine, J., *see* Kaul, P. N., 1745
Hughes, D. W., *see* Gyanchandani, N. D., 224
Huitric, A. C., *see* Camerman, A., 1675
Hunt, J., and Blake, M. I., analysis of *p*-aminosalicylic acid, its salts and dosage forms, by nonaqueous titration, 683
Hussain, A., Trudell, P., and Repta, A. J., quantitative spectrophotometric methods for determination of sodium hypochlorite in aqueous solutions, 1168
Hussain, M., *see* Lien, E. J., 865

I

Idsvoog, P., *see* Perrin, J. H., 1525
Irvin, J. L., *see* Hong, C. I., 1637
Irwin, G. M., Dodson, G. J., and Ravin, L. J., encapsulation of clomacran phosphate[2 - chloro - 9 - [3 - (dimethylamino)-propyl]acridan phosphate] I: effect of flowability of powder blends, lot-to-lot variability, and concentration of active ingredient on weight variation of capsules filled on an automatic capsule-filling machine, 547
Isaacson, E. I., *see* Saenz, R. V., 942
Ishaq, K. S., and Gisvold, O., some cyclic ketals and acetals of digitoxin, digoxin, and ouabain, 412
——*see* Piantadosi, C., 1201
Ismail, A. A., Gouda, M. W., and Motawi, M. M., micellar solubilization of barbiturates I: solubilities of certain barbiturates in polysorbates of varying hydrophobic chain length, 220
——*see* Gouda, M. W., 1402
Iturrian, W. B., and Johnson, H. D., audiosensitization: potential screening method for drugs affecting the CNS, 1046
Iwamoto, R. H., *see* Balazs, M. K., 563
——*see* Goras, J. T., 561

J

Jablon, P. A., Banker, G. S., and Smolen, V. F., *in vitro* and *in vivo* chlorpromazine availability from flocculated polysalt complex systems, 1143
Jakovljevic, I. M., *see* Bishara, R. H., 124
James, T., spectrofluorometric determination of mestranol in oral contraceptive tablets, 1648
Jarboe, R. H., Data, J. B., and Christian, J. E., synthesis of radiolabeled 1,1-bis(*p*-chlorophenyl)-2-nitropropane, 1019
Jarowski, C. I., *see* Forlano, A. J., 121
Jawad, M. J., *see* Kostenbauder, H. B., 1047
Jecklin, T., *see* Khanna, S. C., 614
Jensen, B. L., *see* Harmon, R. E., 576
Jensen, L. H., *see* Camerman, A., 1675
Johns, W. H., and Bates, T. R., quantification of the binding tendencies of cholestyramine II: mechanism of interaction with bile salt and fatty acid salt anions, 329
——and Bates, T. R., quantification of the binding tendencies of cholestyramine III: rates of adsorption of conjugated bile salt anions onto cholestyramine as a function of added inorganic electrolyte concentration, temperature, and agitation intensity, 788
Johnson, B. J., carboxyl protection using salt formation for the synthesis of linear sequential polypeptides: synthesis of poly - (L - tyrosyl - L - glutamyl - L - alanyl-glycyl)glycine-1-^{14}C ethyl ester, 1849
——and Trask, E. G., antigenicity of a polypeptide with a known sequence of amino acids, 724
Johnson, H. D., *see* Iturrian, W. B., 1046
Johnson, H. L., Tsakotellis, P., and DeGraw, J. I., effect of change shielding by nonpolar groups on the partitioning of quaternized amines, 278
Johnson, J., *see* Harmon, R. E., 1694
Johnson, J. B., *see* Carstensen, J. T., 553
Johnson, L., *see* Weltman, A. S., 1659
Johnson, R. E., *see* Crouthamel, W., 878
Jones, R. D. C., Matthews, B. A., and Rhodes, C. T. physical stability of sulfaguanidine suspensions, 518
Judis, J., *see* Boyd, R. F., 81
Jun, H. W., and Triggs, E. J., blood levels of chlorphentermine in man, 306
Jung, W. Y., *see* Samyn, J. C., 169
Jusko, W. J., Leonards, J. R., and Levy, G., riboflavin distribution and elimination in two functionally anephric human patients, 566
——and Levy, G., pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin, 765
——Levy, G., and Yaffe, S. J., effect of age on intestinal absorption of riboflavin in humans, 487
——Levy, G., Yaffe, S. J., and Gorodischer, R., effect of probenecid on renal clearance of riboflavin in man, 473

K

Kabasakalian, P., Katz, M., Rosenkrantz, B., and Townley, E., parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data, 595
Kadaba, P. K., triazolines VI: evaluation of 1,5-diaryl-Δ^2-1,2,3-triazolines and arylidene anilines for herbicidal activity, 1190
Kaistha, K. K., selective determination of isoproterenol and isoproterenol sulfonic acid in pharmaceutical dosage forms, 241
Kakemi, K., Sezaki, H., Mitsunaga, T., and Nakano, M., effect of structural similarity on molecular interaction in aqueous solution: interaction of phenazine and tetramethylpyrimidopteridinetetrone with alkylxanthines and benzene derivatives, 1597
Kalatzis, E., reactions of acetaminophen in pharmaceutical dosage forms: its proposed acetylation by acetylsalicylic acid, 193
Kamel, A. M., Felmeister, A., and Weiner, N. D., interaction of nitrogen dioxide with cholesterol monomolecular films: effect of initial surface pressure, time of exposure, and concentration of nitrogen dioxide, 1807
Kang, S. M., *see* Kapoor, A., 129
Kanig, J. L., *see* Heyd, A., 1171
Kapadia, A. J., Barber, M. A., and Martin, A. E., quantitative determination of butaperazine by TLC, 1476
Kapadia, G. J., acospectoside A III: selective conversion into acovenoside B using snail enzyme with inhibited esterase activity, 723
——and Fayez, M. B. E., peyote constituents: chemistry, biogenesis, and biological effects, 1699
Kaplan, S. A., pharmacokinetic profile of coumermycin A_1, 309
——Lewis, M., Schwartz, M. A., Postma, E., Cotler, S., Abruzzo, C. W., Lee, T. L., and Weinfeld, R. E., pharmacokinetic model for chlordiazepoxide·HCl in the dog, 1569
——Weinfeld, R. E., Cotler, S., Abruzzo, C. W., and Alexander, K., pharmacokinetic profile of trimethoprim in dog and man, 358
Kapoor, A., recent trends in the synthesis of linear peptides, I
——Kang, S. M., and Trimboli, M. A., studies of enzyme active sites: synthesis and catalytic properties of L-histidyl-glycyl - L - aspartyl - L - seryl - L - phenylalanine, 129

Karawya, M. S., El-Kiey, M. A., Sina, A., and Nour, G., simultaneous TLC separation of khelin and visnagin and their assay in *Ammi visnaga* fruits, extracts, and formulations, 1025
——and Ghourab, M. G., assay of chloramphenicol and its esters in formuations, 1331
Karkhanis, P. P., and Anfinsen, J. R., quantitative gas-liquid chromatographic determination of estrone in dermatological products, 535
Katz, M., *see* Kabasakalian, P., 595
Kaul, P. N., Conway, M. W., Clark, M. L., and Huffine, J., chlorpromazine metabolism I: quantitative fluorometric method for 11 chlorpromazine metabolites, 1745
Kaye, T., *see* Ward, C. O., 1661
Keith, L., *see* Dravnieks, A., 495
Kelliher, G. J., and Buckley, J. P., central hypotensive activity of *dl*- and *d*-propranolol, 1276
Kelly, C. A., determination of the decomposition of aspirin, 1053
Kennedy, D. R., *see* McGee, B. J., 1430
Kenner, C. T., *see* Graham, R. E., 1152, 1472
Kessler, W. V., *see* Mork, D. P. S., 803
——*see* Rowles, S. G., 257
Khanna, K. L., *see* Takido, M., 271
Khanna, S. C., Jecklin, T., and Speiser, P., bead polymerization technique for sustained-release dosage form, 614
——and Speiser, P., *in vitro* release of chloramphenicol from polymer beads of α-methacrylic acid and methylmethacrylate, 1398
Khanna, U., *see* Welling, P. G., 1621
Kho, B. T., *see* Krol, G. J., 835, 1483
Kier, L. B., molecular orbital conformation of oxotremorine and a comparison with the muscarinic pattern, 112
Kildsig, D. O., Nedich, R. L., and Banker, G. S., theoretical justification of reciprocal rate plots in studies of water vapor transmission through films, 1634
——*see* Hazlett, J. R., 570
——*see* Heyd, A., 947
Kirschbaum, J., tetrameric structure and conformation of heat-microaggregated human serum albumin, 854
——Slusarchyk, W. A., and Weisenborn, F. L., intermolecular bonding of the antibiotic diumycin, 749
Klayman, D. L., Shine, R. J., and Murray, A. E., Jr., 2-amino-2-oxazoline formation by cyclization of 1-(2-hydroxyethyl)-2-methyl-2-thiopseudourea, 1515
Klein, R., *see* Gruber, M., 830
Knevel, A. M., and Wells, J. N., preparation of ethyl diphenamate in ethanol using potassium diphenimide and 2-chloroethanol, 1844
Knight, J. B., *see* Goras, J. T., 561
Knowles, B., *see* Zatz, J. L., 1188, 1750
Koff, A., *see* Carstensen, J. T., 553
Konyalian, A., *see* Digenis, G. A., 676
Koppanyi, T., *see* MacFarlane, M. D., 1252
Kornblum, S. S., and Hirschorn, J. O., dissolution of poorly water-soluble drugs I: some physical parameters related to method of micronization and tablet manufacture of a quinolinone compound, 606
——and Lopez, B., titanium dioxide lakes I: prepared from certified water-soluble dyes and employed in color-coating tablets, 1016
Korol, B., Zuber, A. V., and Miller, L. D., carotid sinus pressure reflex bioassay for *Veratrum viride*, 1110
Kostenbauder, H. B., Bahal, S. M., and Jawad, M. J., binding of salicylate to crystalline bovine serum albumin and to fraction V bovine serum albumin, 1047
——*see* Nagwekar, J. B., 751, 1775
Kovensky, B. J., and Poole, C. W., colorimetric and gas chromatographic analyses of arecoline in capsule preparations, 1651
Krajny, M., *see* Solymoss, B., 712
Kralik, P. M., *see* Ho, B. T., 1445
Kristiansen, H., Nakano, M., Nakano, N., and Higuchi, T., effect of solvent composition on association between small organic species, 1103
——*see* Huguchi, T., 1601
Krol, G. J., Carney, J. F., and Kho, B. T., quantitative chromatographic analysis of methallibure in animal feed mixtures, 835
——Masserano, R. P., Carney, J. F., and Kho, B. T., quantitative separation of free estrogens by liquid partition chromatography, 1483
Krotoszynski, B. K., *see* Dravnieks, A., 495
Kuang, S. W., *see* Harrell, W. B., 721
Kumler, W. D., *see* Lien, E. J., 1685
Kuriyama, T., Nobutoki, M., and Nakanishi, M., permeability of double-layer films I, 1341
——Nobutoki, M., and Nakanishi, M., permeability of double-layer films II, 1344
——Nobutoki, M., and Nakanishi, M., permeability of double-layer films III, 1412
Kvam, D. C., *see* Updegraff, D. M., 188

L

Lach, J. L., and Bighley, L. D., diffuse reflectance studies of solid–solid interactions, 1261
——*see* Chung, P. H., 1300
——*see* McCallister, J. D., 1286
——*see* Wu, W. H., 1122, 1234
Lamb, D. J., *see* Flynn, G. L., 1433
Lambert, J. P. F., and Margosis, M., rapid determination of aluminum in pharmaceutical dosage forms by neutron activation, 1005
Landolt, R. R., *see* Morris, C. H., 270
Lantz, R. J., Jr., Bailey, A., and Robinson, M. J., monitoring volatile coating solution applications in a coating pan, 1174
LaPidus, J. B., *see* Patil, P. N., 1205
Laskar, P. A., and Mrtek, R. G., synthesis and biological activity of deuteriobenzyl-*d*$_7$-penicillin, 1727
Lasslo, A., *see* Quintana, R. P., 1503
Latham, M. R., *see* Talati, S. M., 491
Lee, A. K. Y., *see* Mezei, M., 858
Lee, K. H., and Tong, T. G., mechanism of action of salicylates VIII: effect of topical application of retinoic acid on wound-healing retardation action of a few anti-inflammatory agents, 1036
——and Tong, T. G., mechanism of action of retinyl compounds on wound healing I: structural relationship of retinyl compounds and wound healing, 851
——and Tong, T. G., mechanism of action of retinyl compounds on wound healing II: effect of active retinyl derivatives on granuloma formation, 1195
Lee, K.-H., *see* Chen, C. H., 1529
Lee, K. P., *see* Welling, P. G., 1621
Lee, T. L., *see* Kaplan, S. A., 1569
Leonards, J. R., and Levy, G., aspirin-induced occult gastrointestinal blood loss: local *versus* systemic effects, 1511
——*see* Jusko, W. J., 566
Leseney, J. L., *see* Barfknecht, C. F., 1842
LeVan, H., Gordon, P., and Stefani, S., enhancement of radioresistance in mice treated with diphenylhydantoin, 1178
Levi, R. S., *see* Hem, S. L., 317, 376
Levine, R. R., and Dizon, C. M., evidence for capacity-limited biotransformation of sulfanilamide, 1845
Levy, G., apparent dose-dependent elimination kinetics as an experimental artifact, 1847
——and Perälä, A., effect of polysorbate 80 and oleic acid on drug absorption from the rat intestine, 874
——*see* Hayton, W. L., 575
——*see* Jusko, W. J., 473, 487, 566, 765
——*see* Leonards, J. R., 1511
——*see* O'Reilly, R. A., 1258
Lewis, M., *see* Kaplan, S. A., 1569
Lewis, R. E., *see* Bhatti, M. C., 368
Li, K. C., *see* Ho, B. T., 1445
Lieberman, S. V., *see* Mueller, F. W., 514
Lien, E. J., Hussain, M., and Tong, G. L., role of hydrophobic interactions in enzyme inhibition by drugs, 865
——and Kumler, W. D., dipole moment and structure of thiophene derivatives and benzene analogs, 1685
——*see* Plakogiannis, F. M., 197
Lim, P., *see* Balazs, M. K., 563
——*see* Goras, J. T., 561
Lin, H. O., and Guillory, J. K., polymorphism in sulfanilamide-d$_4$, 972
Lin, S. L., Menig, J., and Swartz, C. J., comparative evaluation of various dissolution apparatus for capsule dosage forms, 989
Lindstrom, R. E., solubility relationships in urea–water systems, 1695
——and Giaquinto, A. R., salt effects in aqueous solutions of urea, 1625
Lish, P. M., *see* Holck, H. G. O., 1267
Lodge, B. A., and Toft, P., unequivocal distinction between betamethasone and dexamethasone by mass spectrometry, 1045
——*see* Avdovich, H. W., 1164, 1821
Long, J. P., and Chiou, C. Y., pharmacological testing methods for drugs acting on the peripheral nervous system, 133
Loo, J. C. K., and Riegelman, S., assessment of pharmacokinetic constants from postinfusion blood curves obtained after i.v. infusion, 53
Lopez, B., *see* Kornblum, S. S., 1016
Lotti, D. M., *see* Stewart, J. T., 838
Lowenthal, W., Borzelleca, J. F., and Corder, C. D. Jr., drug absorption from the rectum III: aspirin and some aspirin derivatives, 1353
Ludens, J. H., and Williamson, H. E., effects of mefruside on renal hemodynamics, 1841
Ludwig, B. J., *see* Edelson, J., 680
Luzzi, L. A., microencapsulation, 1367
——Zoglio, M. A., and Maulding, H. V., preparation and evaluation of the prolonged release properties of nylon microcapsules, 338

M

MacFarlane, M. D., and Koppanyi, T., acetylcholine tachyphylaxis in isolated rabbit atrium and its relation to norepinephrine stores, 1252
Madan, D. K., and Cadwallader, D. E., effect of macromolecules on aqueous solubility of cholesterol, 1362
Maddox, J. P., *see* Steinberg, G. M., 1107
Magarian, E. O., Christian, S. T., and Clemson, H. C., inhibitory properties of aminoalkylsuccinimides on isolated horse serum butyrylcholinesterase: *N*-methyl-2-phenyl-2-(*tert*-aminoalkyl)succinimides, 1028
——*see* Clemson, H. C., 1137
Magid, L., *see* De Ritter, E., 229
Mahn, F. P., *see* Viswanathan, V., 400
Makhani, M., *see* Farhan, F. M., 1200
Makriyannis, A. C., *see* Smissman, E. E., 1186
Malaiyandi, M., and Barrette, J. P., improved procedure for determination of microamounts of sulfamethazine and procaine penicillin admixed with chlortetracycline and *p*-arsanilic acid in medicated feeds, 568
Malone, M. H., *see* Holck, H. G. O., 1267
Mancott, A., and Tietjen, J., spectrophotometric assay of potassium permanganate tablets (USP XVII), 1482
Mandell, L., *see* Friberg, S., 1001
Mann, D. E., Jr., *see* Burke, D. N., 1814
Mannelli, M., *see* Bottari, F., 1663
Marcus, F., Colaizzi, J. L., and Barry, H., III, pH effects on salicylate absorption from hydrophilic ointment, 1616
Margosis, M., spectral studies of trimethylsilyl ether of chloramphenicol, 501
——*see* Lambert, J. P. F., 1005
Mario, E., and Meehan, L. G., simultaneous determination of nonderivatized phenylpropanolamine, glyceryl guaiacolate, chlorpheniramine, and dextromethorphan by gas chromatography, 538
Martin, A. E., *see* Kapadia, A. J., 1476
Martin, A. R., *see* Green, D. E., 526
Martin, Y. C., and Wiegand, R. G., metabolism and excretion of chromonar and its metabolite in dog and man, 1313
Masserano, R. P., *see* Krol, G. J., 1483
Mathison, I. W., Fowler, W. L., and Fowler, K. C., hydrogenation of substituted isoquinolines over nickel catalyst II: effects of pressure and temperature on the hydrogenation of 5-hydroxy-2-alkylisoquinolinium salts, 998
Matsui, F., *see* Watson, J. R., 391
Matthews, B. A., and Rhodes, C. T., aggregation mechanisms in pharmaceutical suspensions, 1360

——and Rhodes, C. T., use of the Derjaguin, Landau, Verwey, and Overbeek theory to interpret pharmaceutical suspension stability, 521
——*see* Jones, R. D. C., 518
Maulding, H. V., and Zoglio, M. A., complexes of ergot alkaloids and derivatives III: interaction of dihydroergocristine with xanthine analogs in aqueous media, 384
——and Zoglio, M. A., complexes of ergot alkaloids and derivatives IV: investigations into the nature of ergot alkaloid–xanthine complexes, 1673
——and Zoglio, M. A., flexible nonisothermal stability studies, 333
——and Zoglio, M. A., physical chemistry of ergot alkaloids and derivatives I: ionization constants of several medicinally active bases, 700
——*see* Luzzi, L. A., 338
——*see* Zoglio, M. A., 215, 1836
Maynard, W. R., Jr., and Bruce, R. B., GLC determination of guaiacol glyceryl ether in blood, 1346
McCallister, J. D., Chin, T. F., and Lach, J. L., diffuse reflectance studies of solid–solid interactions IV: interaction of bis-hydroxycoumarin, furosemide, and other medicinal agents with various adjuvants, 1286
McDougall, E., *see* DiPasquale, G., 267
McGee, B. J., Kennedy, D. R., and Walker, G. C., some factors affecting release and availability of drugs from hard gelatin capsules, 1430
McGilveray, I. J., *see* Gyanchandani, N. D., 224
McIlhenny, H. M., *see* Sinsheimer, J. E., 622
McIsaac, W. M., *see* Ho, B. T., 573, 1445, 1780
McLaughlin, J. L., *see* Norquist D. G., 1840
Mednick, M. L., *see* Steinberg G. M., 1107
Meehan, L. G., *see* Mario, E., 538
Mehta, A. R., and Staba, E. J., presence of diosgenin in tissue cultures of *Dioscorea composita* Hemsl. and related species, 864
Mehta, C. S., *see* Turner, R. H., 590
Mehta, S. C., Bernardo, P. D., Higuchi, W. I., and Simonelli, A. P., rate of crystal growth of sulfathiazole and methylprednisolone, 638
——*see* Simonelli, A. P., 633
Menczel, E., *see* Ballard, B. E., 714
Menig, J., *see* Lin, S. L., 989
Merritt, E. G., *see* Forlano, A. J., 121
Meulman, P. A., *see* Harmon, R. E., 871
Meyer, M. C., and Guttman, D. E., dynamic dialysis as a method for studying protein binding I: factors affecting the kinetics of dialysis through a cellophane membrane, 33
——and Guttman, D. E., dynamic dialysis as a method for studying protein binding II: evaluation of the method with a number of binding systems, 39
Mezei, M., and Lee, A. K. Y., dermatitic effect of nonionic surfactants IV: phospholipid composition of normal and surfactant-treated rabbit skin, 858
Mickles, J., *see* Foye, W. O., 1348
Mielck, J. B., and Garrett, E. R., kinetics and mechanisms of drug action on microorganisms X: action of spectinomycin on *Escherichia coli* by microbial kinetics, 760
Miele, D., *see* Shane, N., 397
Mika, E. S., *see* Chu, B. L. W., 1508
Mikawa, T., *see* Naito, S. I., 1742
Miles, J. M., *see* Barfknecht, C. F., 1842
Miller, L. D., *see* Korol, B., 1110
Mir, G. M., *see* Huang, C. L., 976
Miskel, J. J., *see* Hom, F. S., 827
Mitsunaga, T., *see* Kakemi, K., 1597
Miya, T. S., *see* Morris, C. H., 325
Mizutani, M., *see* Naito, S. I., 1742
Mohammed, K., Nona, D. A., and Blake, M. I., effect of heavy water on three high producing strains of *Penicillium chrysogenum*, 419
Mollica, J. A., Smith, J. B., Nunes, I. M., and Govan, H. K., kinetics of the decomposition of a Mannich base, 1770
Moore, E. G., *see* Talati, S. M., 491
Moore, G. W., *see* Barr, F. S., 262
Moore, W. E., *see* Shah, P. T., 1034
Mork, D. P. S., Kessler, W. V., and Shaw, S. M., placental transfer of pentobarbital in the rat, 803
Morris, C. H., Christian, J. E., Landolt, R. R., and Hansen, W. G., gas-liquid chromatography of salicylate metabolites, 270
——Christian, J. E., Miya, T. S., and Hansen, W. G., gastric absorption and distribution of acetylsalicylic acid and other compounds in the rat, 325
Morris, R. W., *see* Ebert, W. R., 1409
Morrison, J. C., *see* Bloor, J. R., 387
Motawi, M. M., *see* Gouda, M. W., 1402
——*see* Ismail, A. A., 220
Mrtek, R. G., *see* Laskar, P. A., 1727
Mueller, F. W., and Lieberman, S. V., fitting a double-exponential curve to observed salicylate concentrations in blood, 514
Mufson, D., and Higuchi, W. I., microelectrophoresis and adsorption studies of cholesterol particles in bile salt and alkyl surfactant systems, 601
Muhlhauser, R. O., *see* Block, J. H., 1008
Muis, L. F., *see* Boyd, E. M., 1098
Mukerjee, P., Perrin, J., and Witzke, E., effect of micelle formation on optical rotatary dispersion of β-D-octyl glucoside, 1513
Mukherjee, A. K., *see* Banerjee, S., 273
Muni, I. A., *see* Huang, C. L., 1114
Munno, N., *see* de Silva, J. A. F., 201
Munshi, M. V., *see* Zografi, G., 819
Murray, A. E., *see* Klayman, D. L., 1515
Murray, D. H., and Prokop, J., synthesis of sugar moiety substituted nucleosides I: 9 - [3 - *O* - (*n* - hexyl) - α,β - D - xylofuranosyl]adenine and 9-[3-*O*-(*n*-hexyl)-5-deoxy-α,β-D-xylofuranosyl]adenine, 344
Murthy, K. S., and Rippie, E. G., hydrolysis of procaine and its quaternary derivatives within lyotropic smectic mesophases, 459
——and Zografi, G., oil–water partitioning of chlorpromazine and other phenothiazine derivatives using dodecane and *n*-octanol, 1281
Murty, B. S. R., and Baxter, R. M., new compounds: structural analogs related to asarone and mescaline, 1042
——and Baxter, R. M., spectrophotometric determination of chlorpromazine in pharmaceutical dosage forms, 1010

N

Nagabhushan, M., *see* Patel, N. K., 264
Nagwekar, J. B., and Kostenbauder, H. B., kinetics of elimination of optical isomers of mandelic acid and effect of probenecid on their elimination kinetics in humans, 1775
——and Kostenbauder, H. B., utilization of a model copolymer to evaluate the contribution of hydrophobic bonding in drug binding, 751
——*see* Randinitis, E. J., 806, 813
Naito, S. I., Mizutani, M., Osumi, S., Umetsu, K., Mikawa, T., Nishimura, Y., and Yamamoto, N., biopharmaceutical studies on guaiacol glycerol ether and related compounds IV: drug in blood and bile, 1742
Nakanishi, M., *see* Kuriyama, T., 1341, 1344, 1412
Nakano, M., and Patel, N. K., effect of molecular interaction on permeation of organic molecules through dimethyl polysiloxane membrane, 77
——and Patel, N. K., release, uptake, and permeation behavior of salicylic acid in ointment bases, 985
——*see* Kakemi, K., 1597
——*see* Kristiansen, H., 1103
Nakano, N. I., *see* Kristiansen, H., 1103
Navada, C. K., Chmielewicz, Z. F., and Bardos, T. J., mechanisms of reactions of ring-substituted bis(1-aziridinyl)phosphinyl urethan antineoplastic agents, 1079
Nedich, R. L., *see* Kildsig, D. O., 1634
Nelson, W. L., and Wilson, R. S., muscarinic agents: the isomeric 6-acetoxy-2-methylisoquinuclidine methiodides, 98
——Wong, J. K., Vincenzi, F. F., Blake, P. H., and Smith, D. L., muscarinic receptors: 4-substituted-3-trimethylammoniumtetrahydrofuran halides, 1676
Nematollahi, J., *see* Shihab, F., 1182, 1574
Nessel, R. J., Apelian, H. M., and Blodinger, J., uniformity of distribution of cyanocobalamin in tablet formulations, 254
Neumeyer, J. L., Neustadt, B. R., Weinhardt, K. K., aporphines V: total synthesis of (±)-apomorphine, 1850
Neustadt, B. R., *see* Neumeyer, J. L., 1850
Newmark, H. L., and Berger, J., coumermycin A_1—biopharmaceutical studies I, 1246
——Berger, J., and Carstensen, J. T., coumermycin A_1—biopharmaceutical studies II, 1249
Newton, J. M., *see* Fell, J. T., 688
Ninger, F. C., *see* Goodhart, F. W., 540
Nishimura, Y., *see* Naito, S. I., 1742
Nobles, W. L., *see* Parimoo, P., 1038
Nobutoki, M., *see* Kuriyama, T., 1341, 1344, 1412
Noel, M. B., *see* Ho, B. T., 573
Nona, D. A., *see* Mohammed, K., 419
Norquist, D. G., and McLaughlin, J. L., cactus alkaloids VIII: isolation of *N*-methyl - 3,4 - dimethoxy - β - phenethylamine from *Ariocarpus fissuratus* var. *fissuratus*, 1840
Norred, W. P., Ansel, H. C., Roth, I. L., and Peifer, J. J., mechanism of dimethyl sulfoxide-induced hemolysis, 618
Notari, R. E., Chin, M. L., and Cardoni, A., intermolecular and intramolecular catalysis in deamination of cytosine nucleosides, 28
Nour, G., *see* Karawya, M. S., 1025
Nunes, I. M., *see* Mollica, J. A., 1770
Nunes, M. A., *see* Block, J. H., 1008

O

O'Brien, D. E., and Rost, W. J., *N*-aralkylpiperidyl carbanilates as hypocholesteremic agents, 303
O'Dell, C., *see* Harrell, W. B., 721
O'Dell, C. A., *see* Shealy, Y. F., 1358
Oesterling, T. O., aqueous stability of clindamycin, 63
——and Gustafson, J. H., allylic phosphate hydrolysis: kinetics and mechanism of degradation of 3β,17α-dihydroxy-6α-methylpregn-4-en-20-one 17-acetate, 3-phosphate, 1612
——and Rowe, E. L., hydrolysis of lincomycin-2-phosphate and clindamycin-2-phosphate, 175
Oh, K. H., *see* Foye, W. O., 114
O'Reilly, R. A., and Levy, G., pharmacokinetic analysis of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man, 1258
Osadca, M., *see* De Ritter, E., 229
Ostrenga, J. A., and Steinmetz, C., estimation of steroid solubility: use of fractional molar attraction constants, 414
Osumi, S., *see* Naito, S. I., 1742

P

Packman, D. L., *see* Cullen, L. F., 697
Packman, E. W., *see* Goldstein, F. J., 425
Papariello, G. J., *see* Cullen, L. F., 94, 697
Parimoo, P., and Nobles, W. L., new compounds: some potential chemotherapeutic agents derived from aralkyl ketones, 1038
Paruta, A. N., *see* Breon, T. L., 1306
Pasqualucci, C. R., Vigevani, A., Radaelli, P., and Gallo, G. G., improved differential spectrophotometric determination of rifamycins, 685
Patel, N. K., and Nagabhushan, N., drug–plastic interactions II: sorption of *p*-hydroxybenzoic acid esters by capran polyamide and *in vitro* biologic activity, 264
——and Romanowski, J. M., heterogeneous systems II: influence of partitioning and molecular interactions on *in vitro* biologic activity of preservatives in emulsions, 372
——*see* Nakano, M., 77, 985
Patil, P. N., LaPidus, J. B., and Tye, A., steric aspects of adrenergic drugs, 1205

Paul, A. G., *see* Takido, M., 271
Pearson, J. E., *see* Williams, R. L., 183
Peifer, J. J., *see* Norred, W. P., 618
Perala, A., *see* Levy, G., 874
Perl, W., *see* Cucinell, S. A., 1423
Pernarowski, M., *see* Cho, M. J., 1333
Perrin, J. H., and Hart, P. A., small molecule–macromolecule interactions as studied by optical rotatory dispersion–circular dichroism, 431
——and Idsvoog, P., extrinsic optical activity from a micellar solution, 1525
——*see* Mukerjee, P., 1513
Perry, G. L., *see* Garrett, E. R., 1448
Pfeiffer, R. R., Yang, K. S., and Tucker, M. A., crystal pseudopolymorphism of cephalogylcin and cephalexin, 1809
——*see* Davis, W. W., 960
Phillips, J. R., *see* Cadwallader, D. E., 1234
Piantadosi, C., Ishaq, K. S., and Snyder, F., synthesis of *O*-alkyldihydroxyacetone and derivatives, 1201
——and Snyder, F., plasmalogens and related derivatives: their chemistry and metabolism, 283
——*see* Hong, C. I., 1637
Piccolo, J., and Tawashi, R., inhibited dissolution of drug crystals by a certified water-soluble dye, 56
Pietra, V., and Setnikar, I., testing for uniformity: sampling plans in pharmacopeias for weight, volume, and content uniformity, 530
Pitman, I. H., and Ziser, M. A., thermodynamics and kinetics of covalent addition of bisulfite ion to pyrimidinium ions, 1295
——*see* Dawn, H., 429
——*see* Dawn, H. S., 955
Plakogiannis, F. M., Lien, E. J., Harris, C., and Biles, J. A., partition of alkylsulfates of quaternary ammonium compounds: structure dependence and transport study, 197
Poole, C. W., *see* Kovensky, B. J., 1651
Poole, J. W., and Bahal, C. K., dissolution behavior and solubility of anhydrous and dihydrate forms of Wy-4508, an aminoalicylic penicillin, 1265
——effect of sex on penicillin blood levels in dogs, 1255
Postma, E., *see* Kaplan, S. A., 1569
——*see* Schwartz, M. A., 1800
Poust, R. I., and Smolen, V. F., interaction of hexachlorophene with human epidermis I: *in vitro* bioelectrometric study of pH influence, 1461
Prescott, B., and Caldes, G., potential antitumor agents: derivatives of 2-hydrazino-5-nitropyridine, 101
Prokop, J., *see* Murray, D. H., 344
Puffer, H. W., and Barnett, P. A., polytetrafluoroethylene coating as a suppository mold releasing agent, 848

Q

Quay, J. F., *see* Davis, W. W., 960
Quintana, R. P., Lasslo, A., Garson, L. R., Smith, C. N., and Gilbert, I. H., dermophilic insect repellents with perdurable efficacy, 1503

R

Radaelli, P., *see* Pasqualucci, C. R., 685
Randall, M. J., *see* Evert, C. F., 403
Randinitis, E. J., Barr, M., and Nagwekar, J. B., kinetics of urinary excretion of D(−)-mandelic acid and its homologs II: competitive inhibitory effect of D-(−)-mandelic acid and DL-tropic acid on their renal tubular secretion in rats, 813
——Barr, M., Wormser, H. C., and Nagwekar, J. B., kinetics of urinary excretion of D(−)-mandelic acid and its homologs I: mutual inhibitory effect of D-(−)-mandelic acid and its certain homologs on their renal tubular secretion in rats, 806
Rao, G. S., *see* Sinsheimer, J. E., 622, 629
Rao, K. V., alkaloids of tylophora II: structural studies, 1608
——Wilson, R., and Cummings, B., alkaloids of tylophora I: isolation of six new alkaloids, 1501
Rassaert, C. L., *see* DiPasquale, G., 267
Rattie, E. S., Shami, E. G., Dittert, L. W., and Swintosky, J. V., acetaminophen prodrugs III: hydrolysis of carbonate and carboxylic acid esters in aqueous buffers, 1738
——*see* Ravin, L. J., 1290
——*see* Warren, R. J., 1357
Ravin, L. J., Shami, E. G., and Rattie, E., physical–chemical evaluation of 3-(3-hydroxy-3-methylbutylamino)-5-methyl-*as*, triazino[5,6-*b*]indole (SK&F 30097), 1290
——*see* Irwin, G. M., 547
——*see* Warren, R. J., 1357
Rednick, A. B., *see* Caldwell, H. C., 1689
Reed, J. B., Jr., *see* Das Gupta, V., 1683
Reinhard, J. F., *see* Clemson, H. C., 1137
Repta, A. J., *see* Hussain, A., 1168
Reutrakul, S., *see* Washkuhn, R. J., 779
Rhodes, C. T., Wai, K., and Banker, G. S., molecular scale drug entrapment as a precise method of controlled drug release II: facilitated drug entrapment in polymeric colloidal dispersions, 1578
——Wai, K., and Banker, G. S., molecular scale drug entrapment of a precise method of controlled drug release III: *in vitro* and *in vivo* studies of drug release, 1581
——*see* Bloor, J. R., 387
——*see* Jones, R. D. C., 518
——*see* Matthews, B. A., 521, 1360
——*see* Short, P. M., 995
Rice, R. E., *see* Steinberg, G. M., 1107
Richman, M. D., *see* Contractor, A. M., 1488
Riegelman, S., *see* Barr, W. H., 154, 164
——*see* Chiou, W. L., 937
——*see* Loo, J. C. K., 53
——*see* Rowland, M., 364
——*see* Tingstad, J. E., 692
Rippie, E. G., *see* Murthy, K. S., 459
Robb, B. J., *see* Feldman, J. A., 1646
Robbers, J. E., and Floss, H. G., physiological studies on ergot: influence of 5-methyltryptophan on alkaloid biosynthesis and the incorporation of tryptophan analogs into protein, 702
Robertson, J. E., *see* Updegraff, D. M., 188
Robinson, J. R., and Eriksen, S. P., theoretical approach to sustained-release multiple-dose therapy: noncumulative attainment of desired blood level, 1796
——*see* Washkuhn, R. J., 779
Robinson, M. J., *see* Lantz, R. J., 1174
——*see* Smith, W. E., 776
——*see* Warren, R. J., 109
Roehrig, G. R., *see* Billman, J. H., 861
Roll, W. D., substituted benzamides with potential CNS-depressant and hypotensive activity, 1838
Romanowski, J. M., *see* Patel, N. K., 372
Rose, E. K., *see* Darling, C. M., 1043
Roseman, T. J., and Higuchi, W. I., release of medroxyprogesterone acetate from a silicone polymer, 353
Rosenkrantz, B., *see* Kabasakalian, P., 595
Rost, W. J., *see* O'Brien, D. E., 303
Roth, I. L., *see* Norred, W. P., 618
Rowe, E. L., *see* Oesterling, T. O., 175
Rowland, M., Benet, L. Z., and Riegelman, S., two-compartment model for a drug and its metabolite: application to acetylsalicyclic acid pharmacokinetics, 364
Rowles, S. G., Born, G. S., Christian, J. E., and Kessler, W. V., metabolic fate of 2,3,5-triiodobenzoic acid in laying hens, 257
——*see* Ebert, W. R., 1409
Rubin, S. H., *see* Carstensen, J. T., 553
——*see* De Ritter, E., 229
Russell, A. D., *see* Allwood, M. C., 180
Russell, H. T., *see* Ebert, W. R., 1409
Russo, E. J., and Benney, T. L., pharmaceutical sciences—1969: literature review of pharmaceutics, 883
——*see* Hem, S. L., 317, 376

S

Sabih, Khalid, and Sabih, Khawla, gas chromatographic method for determination of tolbutamide and chlorpropamide, 782
Sabih, Khawla, *see* Sabih, Khalid, 782
Sackler, A. M., *see* Weltman, A. S., 1659
Sackman, P., *see* Shefter, E., 1118
Saenz, R. V., Brown, R. G., Isaacson, E. I., and Delgado, J. N., synthesis of some glycidic hydrazides and amides as potential psychotropic agents and anticholinergic agents, 942
Saettone, M. F., *see* Bottari, F., 1663
Salvino, M., *see* Feldman, S., 705
Sam, J., Shafik, R. M., and Aparajithan K., phenylisoquinolines and hydroisoquinolines, 59
Sampson, C. B., Breunig, H. L., Comer, J. P., and Broadlick, D. E., characterization of the content uniformity plan, 1653
——*see* Comer, J. P., 210
Samyn, J. C., and Jung, W. Y., *in vitro* dissolution from several experimental capsule formulations, 169
Sandmann, B., Szulczewski, D., Windheuser, J., and Higuchi, T., rearrangement of chloramphenicol-3-monosuccinate, 427
Schexnaydre, C., *see* Singh, J. M., 1020
Schmidgall, R. L., *see* Billman, J. H., 1191
Schott, H., bentonite–cellulose systems: flow behavior of mixed dispersions and mechanical properties of composite films, 1492
Schwartz, M. A., and Postma, E., metabolism of flurazepam, a benzodiazepine, in man and dog, 1800
——*see* Kaplan, S. A., 1569
Sciarrone, B. J., *see* Shin, C. T., 297
Scott, G. C., *see* Caldwell, H. C., 1689
Segelman, A. B., and Farnsworth, N. R., penicillin stability to alcohols, 726
Selzer, G. B., *see* Walton, V. C., 1160
Senkowski, B. Z., *see* Viswanathan, V., 400
Sennello, L. T., and Gorski, R. J., improved method for measuring output potential of specific ion electrodes, 1530
Setnikar, I., and Fontani, F., content uniformity in rectal suppositories, 1319
——*see* Pietra, V., 530
Seydel, J. K., *see* Cammarata, A., 1496
Sezaki, H., *see* Kakemi, K., 1597
Shafik, R. M., *see* Sam, J., 59
Shah, P. T., and Moore, W. E., dissolution behavior of commercial tablets extemporaneously converted to capsules, 1034
Shami, E. G., *see* Rattie, E. S., 1738
——*see* Ravin, L. J., 1290
——*see* Warren, R. J., 1357
Shane, N., and Miele, D., fluorometric determination of salicylic acid in aspirin products including noninterfering, interfering, and buffered substances, 397
Shangraw, R. F., *see* Contractor, A. M., 1488
——*see* Vora, K. R. M., 1012
Sharma, R. A., *see* Garg, H. G., 348, 1691
Shaw, S. M., *see* Bhatti, M. C., 368
——*see* Huff, J. E., 126
——*see* Mork, D. P. S., 803
——*see* Wolfangel, R. G., 468
Shealy, Y. F., syntheses and biological activity of 5-aminoimidazoles and 5-triazenoimidazoles, 1533
——and O'Dell, C. A., imidazole and pyrazole bis(2-fluoroethyl)triazenes, 1358
Sheffield, W., *see* Shihab, F., 1182, 1574
Shefter, E., Sackman, P., Stephen, W. F., Jr., and Smissman, E. E., conformations of *erythro*- and *threo*-dimethylacetylcholine iodides in the solid state, 1118
Shenouda, L. S., various species of sulfathiazole form I, 785
Shields, J. K., *see* Wells, J. N., 410
Shihab, F., Sheffield, W., Sprowls, J., and Nematollahi, J., NMR analysis of some alkyl *p*-hydroxybenzoates, 1182
——Sheffield, W., Sprowls, J., and Nematollahi, J., solubility of alkyl benzoates I: effect of some alkyl *p*-hydroxybenzoates (parabens) on the solubility of benzyl *p*-hydroxybenzoate, 1574
Shin, C. T., Sciarrone, B. J., and Discher, C. A., effect of certain additives on the photochemistry of riboflavin, 297
Shine, R. J., *see* Klayman, D. L., 1515
Shipchandler, M., Soine, T. O., and Gupta, P. K., coumarins XI: a total synthesis of (±)-columbianetin, 67
Shishoo, C. J., and Devani, M. B., nonaqueous titrimetric determination of isoniazid in presence of excess of sodium *p*-aminosalicylate in dosage forms, 92
——*see* Devani, M. B., 90

Short, P. M., Abbs, E. T., and Rhodes, C. T., effect of nonionic surfactants on the transport of testosterone across a cellulose acetate membrane, 995
Shroff, A. P., aminosteroids, 110
Sidell, F. R., and Groff, W. A., toxogonin: blood levels and side effects after intramuscular administration in man, 793
Simonelli, A. P., Mehta, S. C., and Higuchi, W. I., inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone, 633
——*see* Ghanem, A. H., 232, 659
——*see* Mehta, S. C., 638
Sina, A., *see* Karawya, M. S., 1025
Singh, H., and Chawla, A. S., *erythrina* sp. III: chemical constituents of *Erythrina suberosa* Roxb. seeds, 1179
Singh, J. M., Fiegenschue, B., and Schexnaydre, C., development of tolerance to pentobarbital, 1020
Singh, P. P., *see* Garg, H. G., 876
Sinsheimer, J. E., and Rao, G. S., constituents from *Gymnema sylvestre* leaves VI: acylated genins of the gymnemic acids—isolation and preliminary characterization, 629
——Rao, G. S., and McIlhenny, H. M., constituents from *Gymnema sylvestre* leaves V: isolation and preliminary characterization of the gymnemic acids, 622
Sjogren, D. W., *see* Holck, H. G. O., 1267
Slusarchyk, W. A., *see* Kirschbaum, J., 749
Smissman, E. E., and Albrecht, W. L., preparation of bis(acetylthiobenzyl)sulfide, 1696
——and Makriyannis, A. C., solvent effects in the NMR spectra of cyano compounds, 1186
——*see* Shefter, E., 1118
Smith, C. I., *see* Teland, V. G., 1521
Smith, C. N., *see* Quintana, R. P., 1503
Smith, D. L., *see* Nelson, W. L., 1676
Smith, E. W., *see* Beyer, W. F., 248
Smith, J. B., *see* Mollica, J. A., 1770
Smith, L. D., *see* Chiou, W. L., 843
Smith, L. L., *see* van Lier, J. E., 719
Smith, N. B., *see* Douglas, J. F., 107
Smith, R. V., *see* Vavrek, R. J., 823
Smith, W. E., Buehler, J. D., and Robinson, M. J., preparation and *in vitro* evaluation of a sustained-action suspension of dextromethorphan, 776
Smolen, V. F., Snyder, D. E., and Erb, R. J., *in vivo* electrometric study of carcinogenic hydrocarbon interaction with mouse epidermis, 1093
——*see* Fites, A. L., 610
——*see* Jablon, P. A., 1143
——*see* Poust, R. I., 1461
Snyder, D. E., *see* Smolen, V. F., 1093
Snyder, F., *see* Piantadosi, C., 283, 1201
Soine, T. O., *see* Chen, C. H., 1529
——*see* Shipchandler, M., 67
Solomon, M. J., and Crane, F. A., critical evaluation of extraction procedures in determination of atropine and scopolamine from *datura* powder, 1680
——and Crane F. A. influences of heredity and environment on alkaloidal phenotypes in solanaceae, 1670
Solvang, S., and Finholt, P., effect of tablet processing and formulation factors on dissolution rate of the active ingredient in human gastric juice, 49
Solymoss, B., Krajny, M., and Varga, S., independence of antimineralocorticoid and catatoxic effects of various steroids, 712
Speiser, P., *see* Khanna, S. C., 614, 1398
Speranza, J. P., *see* Foye, W. O., 259
Spiegel, D., *see* Ahuja, S., 417
Spitzer, C., *see* Ahuja, S., 1833
Sprowls, J., *see* Shihab, F., 1182, 1574
Staba, E. J., *see* Mehta, A. R., 864
Stanley, F., Jr., *see* Harmon, R. E., 1694
Stedman, R. J., *see* Warren, R. J., 1357
Stefani, S., *see* LeVan, H., 1178
Stein, M. L., *see* Franchetti, P., 710
Steinberg, G. M., Mednick, M. L., Rice, R. E., and Maddox, J. P., acetylcholinesterase substrates: β-methylcholine esters, 1107
Steinmetz, C., *see* Ostrenga, J. A., 414
Stephen, W. F., Jr., *see* Shefter, E., 1118
Sternglanz, P. D., determination of dialkyltriazenoimidazoles by nonaqueous titration, 708
Stewart, J. T., and Lotti, D. M., improved colorimetric determination of primary aromatic amines with 9-chloracridine: application to some local anesthetics, 838
Stober, H., *see* Urbanyi, T., 1824
Stockage, J. A., *see* Douglas, J. F., 107, 850
Stone, J. C., objective visual evaluation of the relative content of major and minor defects in tablets and capsules, 1364
Strojny, N., *see* de Silva, J. A. F., 201
Su, K. S. E., *see* Carstensen, J. T., 666, 671
Suzuki, A., Higuchi, W. I., and Ho, N. F. H., theoretical model studies of drug absorption and transport in the gastrointestinal tract I, 644
——Higuchi, W. I., and Ho, N. F. H., theoretical model studies of drug absorption and transport in the gastrointestinal tract II, 651
——*see* Ho, N. F. H., 1125
Swarbrick, J., *see* Augustine, M. A., 314
——*see* Herzog, K. A., 1759
Swartz, C. J., *see* Lin, S. L., 989
Swintosky, J. V., *see* Doluisio, J. T., 72
——*see* Rattie, E. S., 1738
Szulczewski, D., *see* Sandmann, B., 427

T

Takido, M., Khanna K. L., and Paul, A. G., new synthesis of *rac.* anhalonidine and *rac.* pellotine, 271
Takruri, H., *see* Ecanow, B., 1848
Talati, S. M., Latham, M. R., Moore, E. G., Hargreaves, G. W., and Blanton, C. D., Jr., synthesis of potential antimalarials: primaquine analogs, 491
Tan, G. H., *see* Doluisio, J. T., 72
Tansey, L. W., *see* Ho, B. T., 1445
Taraszka, M. J., absorption of clindamycin from the buccal cavity, 873
Tarlin, H. I., determination of ethanol in an elastomeric matrix by gas chromatography, 1184
——and Batchelder, M., determination of total iron in hematinics by atomic absorption spectrophotometry, 1328
Tawashi, R., *see* Piccolo, J., 56
Tejani, B. H., *see* Hem, S. L., 376
Telang, V. G., and Smith, C. I., new compounds: some 3,4,5-trimethoxyphenyl analogs of analgesics, 1521
Thakkar, A. L., solubilization of some steroid hormones in aqueous solutions of bile salts, 1499
——Wilham, W. L., and Demarco, P. V., hydrophobic self-association of *d*-propoxyphene hydrochloride and the effect of urea: a nuclear magnetic resonance study, 281
——Wilham, W. L., and Zografi, G., adsorption of methylene blue by potato starch: effect of methanol, dioxane, sucrose, and urea in aqueous systems, 1466
Thorson, R. E., *see* Digenis, G. A., 676
Tietjen, J., *see* Mancott, A., 1482
Tingstad, J. E., and Riegelman, S., dissolution rate studies I: design and evaluation of a continuous flow apparatus, 692
——*see* Gibson, R. D., 426
Tischio, J., *see* Tometsko, A. M., 1655
Toft, P., *see* Lodge, B. A., 1045
Tolat, S. V., *see* Felmeister, A., 856
Tometsko, A. M., Tischio, J., and Garden, J., II, solid-phase synthesis and degradation of a model polypeptide by an automated approach, 1655
Tong, G. L., *see* Lien, E. J., 865
Tong, T. G., *see* Lee, K. H., 851, 1036, 1195
Townley, E., *see* Kabasakalian, P., 595
Trask, E. G., *see* Johnson, B. J., 724
Triggs, E. J., *see* Jun, H. W., 306
Trimboli, M. A., *see* Kapoor, A., 129
Trudell, P., *see* Hussain, A., 1168
Tsakotellis, P., *see* Johnson, H. L., 278
Tucker, M. A., *see* Pfeiffer, R. R., 1809
Tuckerman, M. M., *see* Acel, K., 1649
——*see* Gibbs, I. S., 395
Turner, R. H., Mehta, C. S., and Benet, L. Z., apparent directional permeability coefficients for drug ions: *in vitro* intestinal perfusion studies, 590
Tye, A., *see* Patil, P. N., 1205

U

Ullah, I., and Cadwallader, D. E., dissolution of slightly soluble powders under sink conditions I: development of an apparatus and dissolution studies of salicylic acid powders, 979
Umetsu, K., *see* Naito, S. I., 1742
Updegraff, D. M., Kvam, D. C., and Robertson, J. E., *N*-(1,1-dihydroperfluorooctyl)-pyridinium trifluoromethanesulfonate, a new quaternary ammonium antiseptic, 188
Urbanyi, T., and Stober, H., fluorometric determination of resperpine and related compounds by reaction with vanadium pentoxide, 1824

V

van Lier, J. E., and Smith, L. L., sterol metabolism X: epimeric 23-hydroxycholesterols, 719
Van Tyle, W. K., and Burkman, A. M., new method for assaying antiapomorphine activity in pigeons, 1757
Varga, S., *see* Solymoss, B., 712
Vavrek, R. J., Cannon, J. G., and Smith, R. V., centrally acting emetic agents IV: synthesis and chromatographic methods for certain nornuciferine derivatives, 823
Venturella, V. S., *see* Viswanathan, V., 400
Verzwyvelt, L. J., *see* Eickholt, T. H., 1518
Viau, J. P., *see* DiCarlo, F. J., 322
Vigevani, A., *see* Pasqualucci, C. R., 685
Vincenzi, F. F., *see* Nelson, W. L., 1676
Viswanathan, V., Mahn, F. P., Venturella, V. S., and Senkowski, B. Z., gas-liquid chromatography of *d*-boitin, 400
Vohra, M. M., *see* Yung, D. K., 1405
Vora, K. R. M., Augsberger, L. L., and Shangraw, R. F., design and evaluation of a pressure attachment for a rotational rheometer, 1012

W

Wagner, J. G., "absorption rate constants" calculated according to the one-compartment open model with first-order absorption: implications in *in vivo–in vitro* correlations, 1049
——*see* Welling, P. G., 1621
Waguespack, G. P., *see* Eickholt, T. H., 1518
Wai, K., *see* Rhodes, C. T., 1578, 1581
Walker, G. C., *see* McGee, B. J., 1430
Walker, K. E., *see* Ho, B. T., 1445
Wall, M. E., *see* Carroll, F. I., 1350
Walton, V. C., Howlett, M. R., and Selzer, G. B., anhydrotetracycline and 4-epianhydrotetracycline in market tetracyclines and aged tetracycline products, 1160
Wang, E. S. N., and Hammarlund, E. R., corneal absorption reinforcement of certain mydriatics, 1559
Warburton, B., *see* Davis, S. S., 1764
Ward, C. O., Barletta, M. A., and Kaye, T., teratogenic effects of audiogenic stress in albino mice, 1661
——*see* Barletta, M. A., 879
Warren, R. J., Stedman, R. J., Shami, E. G., Rattie, E. S., and Ravin, L. J., observations on the micelle formation of 2-butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride (SK&F 33134-A) by NMR spectroscopy, 1357
——and Zarembo, J. E., qualitative and quantitative determination of 1,2- and 1,3-diglycerides by nuclear magnetic resonance spectroscopy, 840
——Zarembo, J. E., Chong, C. W., and Robinson, M. J., determination of trace amounts of water in glycerides by near-infrared spectroscopy, 109
Washkuhn, R. J., Reutrakul, S., and Robinson, J. R., correlation and prediction of rates of alkaline hydrolysis of some benzoate esters, 779
Watson, J. R., Matsui, F., and French, W. N., trifluoperazine tablets: alternative methods of analysis, 391
Watzman, N., *see* Geyer, H. M., III, 964
Weber, D. J., and Higgins, J. W., potentiometric titration of allantoin in cream formulations, 1819

——*see* Garrett, E. R., 1383
Weder, H. J., and Bickel, M. H., interactions of drugs with protein I: binding of tricyclic thymoleptics to human and bovine plasma proteins, 1505
——and Bickel, M. H., interactions of drugs with proteins II: experimental methods, treatment of experimental data, and thermodynamics of binding reactions of thymoleptic drugs and model dyes, 1563
Weiner, N. D., *see* Kamel, A. M., 1807
Weinfeld, R. E., *see* Kaplan, S. A., 358, 1569
Weinhardt, K. K., *see* Neumeyer, K. L., 1850
Weintraub, H., and Gibaldi, M., rotating-flask method for dissolution-rate determinations of aspirin from various dosage forms, 1792
——*see* Gibaldi, M., 725
Weisenborn, F. L., *see* Kirschbaum, J., 749
Welling, P. G., Lee, K. P., Khanna, U., and Wagner, J. G., comparison of plasma concentrations of warfarin measured by both simple extraction and TLC methods, 1621
Wells, J. N., and Shields, J. K., some derivatives of phenethanolamine as MAO inhibitors, 410
——*see* Knevel, A. M., 1844
Weltman, A. S., Sackler, A. M., and Johnson, L., effect of mescaline HCl on resistance of male mice to histamine stress, 1659
Wempe, E., *see* Cammarata, A., 1496
Wesselman, H. J., *see* Gainer, F. E., 1157
West, G. B., *see* Hemsworth, B. A., 118
Westerfeld, W. W., *see* Holck, H. G. O. 1267
Westlake, W. J., time integral of drug concentration in the central (plasma) compartment, 722
White, A. I., *see* Green, D. E., 526
White, M., *see* Calhoun, M. P., 1022
Wiegand, R. G., *see* Martin, Y. C., 1313
Wilham, W. L., *see* Thakkar, A. L., 281, 1466
Williams, P. A., *see* Graham, R. E., 1152, 1472
Williams, R. L., and Pearson, J. E., renal effects of a vasodilator: 2-[*N*-methylpiperidyl-(4)]-3-amino-5(4′-pyridyl)-pyrazole HCl (Ciba 31-531 Ba), 183
Williamson, H. E., *see* Ludens, J. H., 1841
Willix, R. L. S., solute fluxes in fat absorption, 1439
Wilson, R., *see* Rao, K. V., 1501
Wilson, R. S., *see* Nelson, W. L., 98
Windheuser, J., *see* Sandmann, B., 427
——*see* Chu, D., 130
Winslow, D. D., *see* Eickholt, T. H., 1518
Witzke, E., *see* Mukerjee, P., 1513
Wojtowicz, E. J., a column chromatographic method for the determination of sulfanilamide in pharmaceutical preparations containing sulfacetamide or its sodium salt, 240
Wolf, H. H., *see* Cole, H. F., 969
——*see* Yeoh, P. N., 950
Wolfangel, R. G., Shaw, S. M., and Christian, J. E., whole body measurements of ^{131}I-tetracycline as an index of skeletal growth, 468
Wong, J. K., *see* Nelson, W. L., 1676
Wood, J. A., *see* Harder, S. W., 1787
Woods, L. A., *see* Yeh, S. Y., 380
Wormser, H. C., synthesis of azabiotin analogs as potential cofactors for biotin-dependent enzymes, 1732
——*see* Randinitis, E. J., 806
Worthen, L. R., and Bond, H. W., antimicrobial activity of some β-nitrostyrenres, 1185
Wright, G. C., Halliday, R. P., and Davis, C. S., synthesis of new hydrazidines with vasoconstrictor activity, 105
Wu, W. H., Chin, T. F., and Lach, J. L., interaction of ascorbic acid with silicic acid, 1122
——Chin, T. F., and Lach, J. L., interaction of isoniazid with magnesium oxide and lactose, 1234

X

Y

Yaffe, S. J., *see* Jusko, W. J., 473, 487
Yakatan, G. J., *see* Caldwell, H. C., 1689
Yalkowsky, S. H., and Zografi, G., potentiometric titration of monomeric and micellar acylcarnitines, 798
Yamamoto, N., *see* Naito, S. I., 1742
Yang, K. S., *see* Pfeiffer R. R., 1809
Yeh, J. A., *see* Huang, C. L., 772
Yeh, J. Z., *see* Huang, C. L., 976, 1114
Yeh, S. Y., and Woods, L. A., determination of radioactive-labeled codeine, morphine, dihydromorphine, and their metabolites in biological materials, 380
Yeoh, P. N., and Wolf, H. H., pharmacological evaluation of seizures induced by electrical stimulation of the hippocampus, 950
Young, S., *see* Dawn, H. S., 955
Yung, D. K., Vohra, M. M., and Chu, I., potential antiarrhythmic agents II: effects of amide reversal and *ortho*-methylation on activity of procaine amide, 1405
Yunker, M. H., *see* Borodkin, S., 481

Z

Zaharko, D. S., *see* Bischoff, K. B., 149
Zarembo, J. E., *see* Warren, R. J., 109, 840
Zatz, J. J., *see* Carlstadt, B. C., 1456
Zatz, J. L., trace solvent contamination as determined by surface pressure measurement, 117
——and Knowles, B., effect of pH on monolayers of cellulose acetate phthalate, 1750
——and Knowles, B., monomolecular film properties of some cellulose esters, 1188
Zee-Cheng, K. Y., and Cheng, C. C., common receptor-complement feature among some antileukemic compounds, 1630
Zimmerer, R. O., Jr., and Grady, L. T., assay of hyoscyamine, atropine, scopolamine, and phenobarbital in unit doses of tablets and elixirs, 87
——*see* Grady, L. T., 1324
Ziser, M. A., *see* Pitman, I. H., 1295
Ziv, D., *see* Caldwell, H. C., 1689
Zoglio, M. A., and Maulding, H. V., complexes of ergot alkaloids and derivatives II: interaction of dihydroergotoxine with certain xanthines, 215
——and Maulding, H. V., complexes of ergot alkaloids and derivatives V: interaction of methysergide maleate and caffeine in aqueous solution, 1836
——and Munshi, M. V., effect of chemical modification on the surface activity of some phenothiazine derivatives, 819
——*see* Luzzi, L. A., 338
——*see* Maulding, H. V., 333, 384, 700, 1673
——*see* Murthy, K. S., 1281
——*see* Thakkar, A. L., 1466
——*see* Yalkowsky, S. H., 798
Zuber, A. V., *see* Korol, B., 1110
Zuck, D. A., *see* Harder, S. W., 1787

Subject Index

A

Absolute configuration—23-hydroxycholesterols, epimeric, 719
Absorbance ratios—analysis, 1333
Absorption, antibiotics—surfactant effect, 960
comparison method—different formulations, 722
dissolution rates—correlation, 937
distribution, metabolic fate—W-1372-^{14}C, 680
distribution—trimethoprim, 358
drug—surfactant effect, 579
elimination—coumermycin A_1, 309
excretion—pentylenetetrazol-10-^{14}C from sustained-, nonsustained-release tablets, 1409
kinetics—*in vitro* intestinal perfusion, 590
rate, rat intestine—polysorbate 80, oleic acid effects, 874
steroids—*N,N*-dialkylalkylamide effect, 575
Absorption–dissolution, aspirin—correlation, 725
"Absorption rate constants"—one compartment open model, 1049
17β - Acetamido - 6α,16α - dimethylandrost-4-en-3-one—synthesis, 110
Acetaminophen prodrugs—hydrolysis, 1738
reactions—dosage forms, 193
Acetonitrile–diatomaceous earth column—corticosteroid separation, 1472
6-Acetoxy-2-methylisoquinuclidine methiodides—synthesis, 98
Acetylcholine, Ciba 31-351 Ba renal effects—comparison, 183
levels, plasma—determination, 879
tachyphylaxis—isolated atrium, rabbit, 1252
Acetylcholinesterase reactivators—structure–activity relationship, 710
substrates—β-methylcholine esters, 1107
Acetylsalicylate-7-^{14}C, Na—absorption, distribution, 325
Acetylsalicylic acid—pharmacokinetics, 364
Acid-dye method—trifluoperazine analysis, 391
Acidic compounds—acetylsalicylate-7-^{14}C, Na—absorption, distribution comparison, 325
Acospectoside A, hydrolysis—snail enzyme, 723
Acovenoside B formation—acospectoside A hydrolysis, 723
***N*-Acrylyltryptamines** and *N*-crotonyltryptamines—synthesis, 573
Activation energies, entropies—procaine, derivatives, in lyotropic mesophases, 459
Acute toxicity—MBR 3092-42, 188
mice—2-hydrazino-5-nitropyridines, 101
Acylcarnitines, monomeric, micellar—potentiometric titration, 798
Addiction, habituation, tolerance—mescaline, 1699
Additives, single, multiple feedings—penicillin production, *P. chrysogenum*, 419
Adjuvant effect—liquid, tablet surface contact angle, 1787
Adrenal ascorbic acid—acute stress index, 126
β-Adrenergic blocking activity—propranolol, 1276
Adrenergic drugs—steric aspects, 1205
α,β-Adrenergic receptors—drug interaction, 1205
Adsorption chromatography—identification, 719
—organic compounds on filters, 843
studies—cholesterol–bile salts, surfactant interactions, 601
Aeration, shaking effect—penicillinase production, 81
Aerosol meter valves—dosage weight variation, 1488
Age effect—riboflavin intestinal absorption, 487
of mice, effect—induced hypothermia, 1814
Aggregated gelatin encapsulated hexadecane droplets—solute transport, 659
Aggregates, diumycin A, B—ethanolic aqueous buffers, 749
Aggression—genetic predisposition, mice, 969
Agitation rate effect—rate transport pH profiles, 644
temperature effects—anion adsorption, cholestyramine, 788
Albumin, human serum, heat-microaggregated—tetrameric structure, conformation, physical constants, 854
Alkaline hydrolysis rates—benzoate ester identification, 779
Alkaloids, cactus—isolation, identification of constituents, 1840
—*Tylophora crebriflora*, 1608
Alkylating activity—*cis*-, *trans*-2,3-dimethylaziridine analogs, 1079
***O*-Alkyldihydroxyacetone,** derivatives—synthesis, 1201
Alkyl *p*-hydroxybenzoates—NMR analysis, 1182
N-(*p*-tosyl)carbamates—formation, synthesis, 1663
Allantoin cream formulation—analysis, 1819
Alumina gels, amorphous, effect—Al_2O_3 conversion, 376
Aluminum in dosage forms—determination, 1005
Amides, glycidic—synthesis, 942
Amine drugs—interaction, polycarboxylic acid ion-exchange resin, 481
Amines—"indirectly" acting, 1205
primary aromatic—improved analysis, 838
quaternized—partitioning, 278
Amino acid sequence, computer controlled—polypeptide synthesis, 1655
protecting groups—peptide synthesis, 1
2 - Amino - 4 - carbamyl - 6 - methoxy - 4-methyltetralin—synthesis, 526
2′ - Amino - 4′,5′ - dichlorobenzenesulfonanilide, Schiff bases—synthesis, antitumor activity evaluation, 1191
2-Amino-1,6-dihydro-4-methylpyrimidinium-6-sulfonate—synthesis, 1295
2 - Amino - 1,6 - dihydropyrimidinium - 6-sulfonate—syntheses, 1295
Aminoethanethiol *S*-sulfonic acids, *N*-substituted—radioprotective capacity, structure–activity relationships, 1350
Aminoethanethiols, *N*-substituted—radioprotective capacity, structure–activity relationships, 1350
5-Aminoimidazoles—methods of synthesis, 1533
2-Amino-2-oxazoline formation—using, thiopseudoureas, cyclization, 1515
2 - Amino - 4 - phenyl - 5 - arylazothiazoles—synthesis, 348
8-Aminoquinolines—synthesis, 491
***p*-Aminosalicylic** acid and salts—analysis, 683
Aminothiophenes, dithiocarbamate derivatives—radiation-protective capacity, antimalarial properties, 1348
2′ - Amino - *p* - toluenesulfonanilide, Schiff bases—synthesis, antitumor activity evaluation, 1191
Amobarbital-^{14}C metabolism—acute, chronic stress effect, 126
Ampicillin effect—respiratory tract, 556
Ampuls—oxygen determination, 94
Analgesic activity—2-amino-4-carbamyl-6-methoxy-4-methyltetralin, 526
properties—derivatives of benzoic, cinnamic acids, esters, 422
Analog computer generated curves, experimental data curves—comparison, 72
Analytical methods—salicylic acid in aspirin and aspirin products, 1053
Anephric condition—riboflavin distribution, elimination, 566
Anesthetic properties—derivatives of benzoic, cinnamic acids, esters, 422
Anhalonidine, racemic—synthesis, 271
Anhydrotetracycline determination—tetracycline products, 1160
Animal feed mixtures—methallibure determination, 835
Anorexigenic activity—benzyloxyamines, 1752
Antiarrhythmic agents, potential—synthesis, 1405
Antibacterial activity—*N,N*-dialkylamino-1,2,3-triazoles, α-diazoamidines, 1694
activity—1 - styryl - 3,4 - dihydroisoquinolines, 576
Antibiotics, dicloxacillin—effect, respiratory tract, 1198
Anticancer activity—5-substituted pyrimidine-6-carboxaldehydes, 1637
agents, potential—synthesis, 276
drugs—purity determination, 708
Anticholinesterase activity—physostigmine degradation products, 118
Anticonvulsant activity—*N*-methyl-2-phenylsuccinimide derivatives, 1137
Anticonvulsants effect—electrically produced seizures, 950
Antidiabetics—synthesis, pyrazoles, isoxazoles, 876
Antigenicity—polypeptide, 724
Anti-inflammatory activity—benzyloxyamines, 1752
agents, wound-healing retardation—retinoic acid inhibition, 1036
Antileukemic activity—triazenoimidazoles, 1358
compounds—common receptor complement, 1630
Antimalarial activity—8-aminoquinolines, 491
activity—benzyloxyamines, 1752
activity—bis-(4-aminophenyl) disulfide derivatives, 259
Antimalarials, evaluation—*p*-sulfamoylphenylazo compounds, 1031
Antimicrobial activity—bisphenol–organomercurial combinations, 262
activity—MBR 3092-42, 188
activity—perphenazine dimethiodide-^{14}C, 976
activity, evaluation—β-nitrostyrene derivatives, 1185
activity, parabens—capran polyamide sorption effect, 264
preservatives—hemolytic activity, 478
Antimineralocorticoid activity—steroids, 712
Antineoplastic activity—triazenoimidazoles, 1533
agents—reaction mechanisms, 1079
Antineoplastics—2,4-diamino - 6 - hydroxy-5-arylazopyrimidines, 1,3-dimethyl-5-arylhydrazonoalloxans, synthesis, 1691
Antiradiation compounds—dithiocarbamates of aminothiophenes, 1348
compounds—synthesis, 114
Antitumor activity evaluation—2′-amino-4′,5′-dichlorobenzenesulfonanilide, 2′-amino-*p*-toluenesulfonanilide, 1191
agents—synthesis, 1,3,2-dioxaphosphorinane 2-oxides, 861
(±)-Apomorphine—total synthesis, 1850
Apomorphine-induced pecking syndromes, pigeons—as assay method, 1757
Aralkyl ketone derivatives—synthesis, structure–activity relationships, 1038
***N*-Aralkyl-piperidyl** carbanilates, ureas—synthesis, 303
***N*-Aralkyl-piperidylideneimino** urethans—synthesis, 303
Arecoline capsules—analysis, 1651
Ariocarpus fissuratus—*N*-methyl-3,4-dimethoxy-β-phenethylamine isolation, 1840
Arrhenius least-squares equations, thermal stability—comparison, evaluation, 464
Arylidene anilines—herbicidal activity, 1190

Asarone, mescaline trimethoxyphenyl derivatives—synthesis, 1042
Ascorbic acid effect—disulfiram activity, 1267
—stability, biological availability, 229
Ascorbic acid–silicic acid—solid-state interaction, 1122
Aspirin—acetaminophen acetylation, 193
decomposition—determination, 1053
derivatives—drug absorption, rectum, dog, 1353
dosage forms—dissolution, absorption, 725
dosage forms—salicylic acid determination, 397
in dosage forms—dissolution rates, 1792
—induced gastrointestinal blood loss, local *versus* systemic effects, 1511
release, capsules—excipient effect, 1430
Atomic absorption spectroscopy—analysis, 368, 712, 1328
Atropine effect—acetylcholine tachyphylaxis, 1252
homatropine, scopolamine dosage forms—analysis, 1646
scopolamine dosage forms—analysis, 1324
scopolamine, extraction from *Datura* powder—comparison, evaluation of various procedures, 1680
Audiogenic stress, effects—teratogenicity, albino mice, 1661
Automated dispensing analyzer, tablet—construction, operation, 248
extraction procedure—phenmetrazine HCl analysis, 1833
methods—digitoxin, digoxin, unit dose analysis in tablets, diagram, 697
system—peptide synthesis, degradation, 1655
tablet coating—radio frequency system, moisture measurement, 1171
Automatic analyzer—diagram, digitoxin, digoxin determination, 697
Autonomic drugs effect—oxotremorine, sodium nitroprusside-induced hypothermia, 1814
Autoradiography—analysis, 325
3 - Aza - 17β - acetamido - 6α,16α - dimethyl - androst-4a-en-4-one—synthesis, 110
Azabiotin analogs—synthesis, 1732

B

Bacillus subtilis—ethylene oxide penetration determination, 717
Barbital, molecular association—caffeine in 2:1 crystalline complex, 1666
Barbiturates, 5,5-disubstituted—solubility, 1402
solubility—ethanol–water systems, 1306
—solubilization, 220
Barbituric acid derivatives—absorption, diffusion data, rats, 651
Behavioral response, learned, unlearned—antidepressants, tranquilizer effects, 964
Bentonite–cellulose systems—flow behavior, mechanical properties, 1492
Benzoate esters—alkaline hydrolysis rates, 779
Benzoic acid, esters (derivatives)—synthesis, biological evaluation, 422
—solubilization study, 1427
Benzyl alcohol—subcutaneous absorption, 714
Benzyloxyamines—synthesis, 1752
Bile salts, fatty acid salt anions—cholestyramine interaction mechanism, 329
Binary mixture analysis—reference spectrum, 1333
Binders effect—tablet dissolution, 49
Binding sites—copolymer–*p*-toluene sulfonate ions, 751
Bioanalysis—digitoxin, digoxin, ouabain derivatives, 412
Bioelectrometric determination—epidermis–hydrocarbon interaction, 1093
study—pH effect, hexachlorophene–human epidermis interaction, 1461
Biogenesis—peyote alkaloids, 1699
Biologic half-life, warfarin—phenylbutazone effect, 1258
Biological activity correlation—physicochemical data, 215
activity—deuteriopenicillin, 1727
activity, dihydroergocristine—xanthines, effect, 384
activity—emulsion preservatives *in vitro*, 372
activity — 2 - hydrazino - 5 - nitropyridines, 101
assay—physostigmine degradation products, 118
availability, ascorbic acid—silica gel effect, 229
effects—peyote constituents, 1699
fate—mepazine and promethazine ^{14}C-methiodides, 772
Biomembrane model, polymeric—drug permeation, 1759
Biopharmaceutics—1969 literature review, 883
Biosynthesis, deuterated benzylpenicillin—*P. chrysogenum* cultures, 1456
—plasmalogens, 283
***d*-Biotin**—determination, 400
Biotin-dependent enzymes—potential cofactor, azabiotin analogs, 1732
Biotransformation, distribution—quaternary phenothiazine compounds, 1114
dogs—chlordiazepoxide·HCl, 1569
sulfanilamide—rate limited, 1845
Bis(acetylthiobenzyl)sulfide—synthesis, 1696
Bis-(4-aminophenyl) disulfide and thiosulfinate—*N*-acyl derivatives synthesis, 259
5(or 4)-[3,3-Bis(2-chloroethyl)-1 triazeno] imidazole-4(or 5)-carboxamide—quantitative analysis, stability, 1829
1,1 - Bis(*p* - chlorophenyl) - 2 - nitropropane—synthesis, specific activity, 1019
Bis(2-fluoroethyl)triazene derivatives—synthesis, 1358
(±)-Bisnorargemonine—synthesis, 1529
Bis - (*trans* - 2,3 - dimethylaziridinyl)phosphinyl urethan—synthesis, 1079
Bisulfite ion, kinetics, thermodynamics—covalent addition to pyrimidinium ions, 1295
Blood cells, number—disulfiram effect, 1267
concentration data—evaluation, basic aspects, 514
levels, chromonar and acid metabolite—human, dog, 1313
levels, coumermycin A_1—administration route effect, 1249
levels, coumermycin A_1—formulation effect, 1246
levels, half-life, corticosteroids—sex effect, dogs, 1255
levels—noncumulative multiple-dose therapy, 1796
pressure changes—pentaerythritol tetranitrate release, 273
urine analysis—*N*-1-substituted nitroimidazoles, 201
Blue tetrazolium, phenylhydrazine, isonicotinic acid hydrazide methods—corticosteroid analysis, 1472
phenylhydrazine, isonicotinic acid hydrazide, UV spectrophotometry methods—analysis, 1152
Bond formation—peptides, 1

Books
Acetylenes and Allenes: Addition, Cyclization, and Polymerization Reactions, 132
Actualites Pharmacologiques, 882
Addendum 1969 to the British Pharmacopoeia 1968, 578
Adrenergic Neurotransmission, 132
Aktuelle Probleme der Toxikologie und Angrenzender Gebiete, 1854
American Drug Index, 882
Amino Acides Peptides Proteines, 132
Amphetamine Abuse, 131
Antibiotics in Clinical Practice, 1698
Antibiotike-Fibel—Antibiotika und Chemotherapie, 132
Aromatic Nucleophilic Substitution, 577
Arzneimittelwirkungen. Ein Lehrbuch, der Pharmakologie fur Pharmazeuten, Chemiker und Biologen, 1698
Autoxidation of Hydrocarbons and Polyolefins: Kinetics and Mechanisms, 131
Bacterial Episomes and Plasmids, 578
Behavior of Enzyme Systems, 132
Biochemical and Clinical Aspects of Alcohol Metabolism, 730
The Biochemistry of Alkaloids: Molecular Biology, Biochemistry and Biophysics, 729
The Biochemistry of Folic Acid and Related Pteridines, 578
Biochemistry of Mental Disorders: Report of a WHO Scientific Group, 730
Biologically Active Amines Found in Man, 1051
British Medical Bulletin: Control of Human Fertility, 881
British National Formulary 1968, 132
British Pharmaceutical Codex 1968, 132
Cationic Surfactants, 1365
Chemical and Botanical Guide to Lichen Products, 730
Chemical Control of Fibrinolysis-Thrombolysis, 1698
Chemical Engineering Kinetics, 1854
Chemico-Biological Interactions, 882
The Chemistry and Biochemistry of Steroids, 1853
The Chemistry and Physics of High Energy Reactions, 577
Chirurgenverzeichnis, 1204
Chromatography, 882
Circulatory and Respiratory Mass Transport, 730
Clinical Endocrinology, 1854
Clinical Pharmacology (Dilling), 578
Clinical Pharmacology Scope, Organization, Training, 1698
Clinical Pharmacy Handbook, 1051
Clinical Toxicology, 881
Codeine and Its Alternates for Pain and Cough Relief, 1366
Comparative and General Pharmacology, 1204
A Comprehensive Guide to the English-Language Literature on Cannabis, 578
Consulting. Establishing and Maintaining An Independent Practice, 1366
Contraception: The Chemical Control of Fertility, 1203
The Control of Chemotherapy, 1698
Current Index of Conference Papers in Life Sciences, 882
Cytologie Moleculaire Des Membranes Et Compartiments De La Cellule Animale, 1854
Cytotoxic Drugs in the Treatment of Cancer, 1854
Degradation of Herbicides, 132
Describing Chemical Engineering Systems, 882
Deutsches Arzneibuch 7, Ausg. 1968 Kommentar, 578
The Dictocrats. Our Unelected Rulers, 1698
Die Interkantonale Vereinbarung uber die Kontrolle der Heilmittel vom 16. Juni 1954, 132
Drug Abuse: Social and Psychopharmacological Aspects, 729
Drugs and Youth, 729
Drugs in Current Use and New Drugs, 730
Electrometric Methods, 882
Emergency Health Services Digest, 882
Encyclopedia of Industrial Chemical Analysis, Vol 8, 578
European Pharmacopoeia, 1532
Experimental Medicine and Surgery, 882
Experimental Methods in Pharmacology, 728
Foetal Autonomy, 1204
Gas Chromatography in Biology and Medicine, 1697
Gas Chromatography in Biology and Medicine. A Ciba Foundation Symposium, 730
Gas-Liquid Reactions, 1204
Genetics of Antibiotic-producing Microorganisms, 578
Hagers Handbuch der Pharmazeutischen Praxis, 882
Handbook of Experimental Pharmacology, 882
Handbook of Experimental Pharmacology: Diuretica, 730
Health in a Bottle: Searching for the Drugs That Help, 882
The History of Penicillin Production, 1697
Homeostatic Regulators, 1204
Human Ecology and Public Health, 1050
Index Nominum 1966, Supplementum 1968, 132
Industrial Toxicology, 729
Ingredient X. The Production of Effective Drugs, 1204
International Encyclopedia of Pharmacology and Therapeutics, 1852
An Introduction to Chromatography on Impregnated Glass Fiber, 578
Introduction to the Chemistry of Enzyme Action, 1854
Isolation and Identification of Drugs (in Pharmaceuticals, Body Fluids and Post-mortem Material), 1203
Journal of Texture Studies. An International Journal of Rheology, Psycho-

rheology, Physical and Sensory Testing of Foods and Pharmaceuticals, 882
Legal Medicine Annual, 1203
The Lynn Index—A Bibliography of Phytochemistry, 730
Marine Pharmacology, 1204
Medicaments Organiques de Synthese, 132
Medicaments Organiques de Synthese II, 578
Methodenlehre der therapeutisch-klinischen Forschung, 577
Methods of Biochemical Analysis, Vol. 18, 1204
Methods of Biochemical Analysis, 132
Microbiologie Industrielle et Genie Biochimique, 1204
Modern Microcrystal Tests for Drugs, The Identification of Organic Compounds by Microcrystalloscopic Chemistry, 1698
Molecular Biology, Biochemistry, and Biophysics, 730
The Molecular Orbital Theory of Organic Chemistry, 430
Mutation as Cellular Process, 1204
II. Nachtrags-und Erganzungsband Gehes Codex, 730
The National Formulary, Thirteenth Edition, 1052
Neurophysiological and Behavioral Aspects of Psychotropic Drugs, 881
Neuropsychopharmacology and the Affective Disorders, 1854
New Dimensions in Legal and Ethical Concepts for Human Research Vol. 169, art. 2, 1051
Non-Specific Factors in Drug Therapy, 131
Nursing Home Standards: A Tragic Dilemma in American Health, 1854
One-Dimensional Two-Phase Flow, 882
Oral Hypoglycaemic Agents, 730
Parathyroid Hormone, Thyrocalcitonin and Related Drugs, 1698
Parenteral Dosage Forms, 1051
Pharmaceutical Abstracts, 578
Pharmaceutical Abstracts, 882
Pharmaceutical Advertising, 1968 Revision, 730
Pharmaceutical Chemistry, Part II, 132
Pharmaceutical Chemistry, Volume 2: Instrumental Techniques, 1365
Pharmaceutical Enzymes and Their Assay, 880
Pharmaceutical Handbook, 1204
Pharmaceutics—Galenical Pharmacy, 577
Pharmacological Facts and Figures, 882
Pharmacological Research Communications, 132
Pharmacology of the Endocrine System and Related Drugs: The Neurohypophysis, 1853
Pharmacology and Patient Care, 1532
Pharmacology for the Preoperative Visit, 132
Physician's Book Compendium, 1203
Practical Optical Crystallography, 2nd Edition, 578
Precis de Microbiologie, 132
Primer of Immunoelectrophoresis, 1854
Principles for the Testing and Evaluation of Drugs for Carcinogenicity: Report of a WHO Scientific Group, 730
Principles of Physical, Organic, and Biological Chemistry, 430
Proceedings of the Institute on Drug Literature Evaluation, 578
Programmed Thermodynamics, 1698
The Psychopharmacology of the Normal Human, 132
Psychotropic Drug Response: Advances in Prediction, 132
Purification of Inorganic and Organic Materials: Techniques of Fractional Solidification, 132
Review of Biochemistry, 881
The Role of Learning in Psychotherapy, 132
Spectroscopy, 882
Steroid Reaction Mechanisms, 132
Subsidia Pharmaceutica 1968, 578
Subsidia Pharmaceutica, 1854
Techniques of Medication, 729
The Theory and Practice Industrial Pharmacy,1531
Thin-Layer Chromatography, 1365
Verstandliche Wissenschaft, Band 99, 578
Welfare Medical Care: An Experiment, 578
WHO Expert Committee on Drug Dependence, 882
WHO Expert Committee on Specifications for Pharmaceutical Preparations: Twenty-second Report, 578
Bovine serum albumin, crystalline, Fraction V—salicylate binding comparison, 1047
Bradykinin-induced writhing test—biological analgetic screening, 422
Bratton-Marshall reaction—colorimetric analysis, 568
Bronchospasm—comparison antibiotics, effects, 1198
Buffer effect—corneal absorption, 1559
Butaperazine in dosage forms—analysis, 1476
2 - Butyl - 3 - benzofuranyl - 4 - [2 - (diethylamino)ethoxy]-3,5-diiodophenyl ketone hydrochloride (SK & F 33134-A)—micelle formation, 1357
Butyrylcholinesterase inhibition—aminoalkylsuccinimides, 1028

C

Caffeine–Na benzoate—spectral characteristics, 1333
Capran polyamide sorption effect—paraben antimicrobial activity, 264
Capsule dosage forms—dissolution apparatus, 989
Capsules, hard gelatin—drug release, availability, 1430
—*in vitro* dissolution, 169
soft elastic, tablets—drug release-rate comparison, 827
1 - Carbamoyl - 3,5 - diphenyl - 4 - arylazopyrazoles—synthesis, potential hypoglycemics, 876
β-Carbolines, 6(or 8)-substituted—synthesis, 1445
Carbonate, carboxylic acid esters of prodrugs—hydrolysis, aqueous buffers, 1738
Carboxyl protection—peptide synthesis, 1, 1849
Carcinogenic hydrocarbon interaction—mouse epidermis, 1093
Carotid sinus pressure reflux—*V. viride* bioassay, 1110
Catalysis, inter- and intramolecular—cytosine nucleosides, 28
Catatoxic activity—steroids, 712
Catecholamines, brain—propranolol effect, 1276
Cellulose acetate phthalate monolayers—pH effect, 1750
esters—monomolecular film properties, 1188
microcrystalline—implantation pellets, 426
Cellulose–bentonite systems—flow behavior, mechanical properties, 1492
Cephaloglycin, cephalexin—pseudomorphic crystallization, 1809
Cetomacrogol 1000 solution—benzoic acid solubility, 1427
Charge density, fixed—human epidermis, 1461
shielding, nonpolar groups, effect—quaternized amine partitioning, 278
Chemical balance—used as rheometer, 1764
equilibria, mass transfer—two phase compartment model, 644
Chemistry, plasmalogens—related derivatives, 283
Chemotherapeutic agents—aralkyl ketone derivatives, synthesis, 1038
Chlorambucil analysis—4-{*p*-[(2-chloroethyl)-(2-hydroxyethyl)amino]phenyl} butyric acid interference, 563
Chloramine determination—Na hypochlorite analysis, 1168
Chloramphenicol esters in dosage forms—analysis, 1331
release—α-methacrylic acid, methylmethacrylate beads, 1398
thermal stability—statistical determination, 464
Chloramphenicol - 3 - monosuccinate — rearrangement, 427
Chlordiazepoxide·HCl and metabolites, disposition—pharmacokinetic model, 1569
Chlorine potential—N-chlorosaccharin, 955
substitution, *N*-acrylyltryptamines and *N* - crotonyltryptamines — hydroxyindole-*o*-methyltransferase inhibition, 573
9-Chloroacridine solution—stabilization, 838
N - **(2 - Chlorocyclohexyl) - saccharin**—synthesis, structure, formation rate, 429
4 - {*p* - [(2 - Chloroethyl) - (2 - hydroxyethyl)-amino]-phenyl} butyric acid—synthesis, 563
***N*-Chlorosaccharin**—cyclohexene addition, 429
—synthesis, 955
Chlorphenesin in plasma—determination, 107
Chlorphentermine blood levels—determination, 306
Chlorpromazine dosage forms—analysis, 1010
imipramine, thiazesim—comparative effects, learned, unlearned behavior, 964
—metabolism, 1745
oil–water partioning—dodecane, *n*-octanol, 1281
Chlorpromazine HCl, chlordiazepoxide, Na pentobarbital effect—aggression, 969
Chlorpromazine-^{35}S–polysalt complex systems—*in vivo, in vitro* availability, 1143
Chlorpropamide in biological fluids—determination, 782
Chlortetracycline—analysis, separation in tetracycline, 558
Cholesterol biosynthesis—*E. granulosus* scolices, 676
cholesterol-26-^{14}C solubility—macromolecule effects, 1362
excretion—guaiacol glycerol ether mononicotinate effect, 1742
interphase transport—aqueous polysorbate 80–hexadecane system, 744
monomolecular films—nitrogen dioxide interaction, 1807
surface, interaction—bile salts, alkyl surfactants, 601
Cholestyramine binding—conjugated bile salt anions, 788
binding—quantification, 329
Chromatography, liquid–liquid, thin-layer—separation, analysis, 427
liquid partition—separation, 1483
Chromonar—metabolism, excretion, 1313
Chrysene—internal standard, 561
α-Chymotrypsin—structure–activity relationship, 731
Cinnamic acid, esters (derivatives)—synthesis, biological evaluation, 422
Claviceps purpurea growth—tryptophan analogs, 1149
Clindamycin—buccal abso ption, 873
—stability, aqueous solution, 63
Clindamycin 2-PO_4—hydrolysis kinetics, 175
Clinical studies—5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, 5-[3,3-bis(2-chloroethyl) - 1 - triazeno]imidazole - 4-carboxamide, 1533
Clomacran PO_4—encapsulation, 547

CMC—acylcarnitines, 798
CNS active drugs—screening method, 1046
activity—1,2-diphenylindolizine derivatives, 275
activity—imidazo(4,5-*d*)pyridazines, 1584
depressant activity—synthesis, pharmacological evaluation of *N*-cyclohexyl nitrobenzamide analogs, 1838

Coacervation simple, complex—microencapsulation, 1367
Coagulation—suspensions, 521
Coal tar solution—analysis, 830
Coating application, pellets—monitoring method, 1174
Coatings, tablet—drug content relationship
Cobalt determination—vitamin B_{12} dosage forms, 1200
Codeine, metabolites—determination, biological samples, 380
Codeine PO_4, caffeine effect—acetaminophen stability, 193
Coefficient of variation, dosage forms—equations, 530
Collaborative study—membrane filtration, insulin sterility, 1022
Color coating, tablets—titanium dioxide lakes, 1016
Colorimetric analysis, 1008
analysis—phenol red, 705
analysis—spectrophotometer, 77, 124, 130, 175, 384, 391, 563, 685, 757, 788, 838, 879, 1010, 1149, 1160, 1328, 1331, 1466, 1480, 1482, 1483, 1646, 1651, 1742, 1807, 1829
reaction—stabilization, 417
Colorimetry—analysis, gels, 376
analysis—spectrophotometer, 395
(±)-Columbianetin—total synthesis, 67
Column chromatography—analysis, 391
—separation, 240, 270, 344, 622, 683, 835, 1025, 1160, 1420, 1470, 1472, 1480, 1819
—separation, purification, 782

Complex formation—solvent composition effect, 1103
Complexes, organic molecular—aqueous solution, 1271
thiouracil–metal—stability constants, 1383
Compression effect—tablet fracture, 688
Computer program—conversion of light-scattering data to micellar molecular weights, 387
program—data fitting, models, 403
simulation—drug distribution, tablets, 210
Concentration effect, clomacran PO_4—capsule weight variation, 547
phenothiazines—surface activity, 819
Concentration–time curve areas, ratio—drug–metabolite, 364
Conformation, structural—*erythro-* and *threo-*α,β-dimethylacetylcholine, 1118
Conformational molecular preference—oxotremorine, 112
studies—heat-microaggregated human serum albumin, 854
Conjugation, intestinal—salicylamide, glucuronic acid, 164
Contaminants in solvents—surface pressure effect, 117
Content uniformity method—atropine, scopolamine dosage forms, 1324
suppositories—official specifications, 1319
tablets—sampling plan, 1653
Convulsive seizures—electrical stimulation, hippocampus, 950
Core size, tablets—coating drug content variation, 553
Corneal absorption, mydriatics—reinforcement, 1559
Corticoid administration, chronic—Ca effect evaluation, 368
Corticosteroid dosage forms—analysis, 1472
Corticosteroid-21-phosphate esters—solvolysis, micelle formation, 1433
Corticosteroids, decomposition determination—methods compared, 1152
1,4-dien-3-one type—analysis, 1164
Cotton effect—molecular binding, 431
Coumarins—*Prunus mahaleb* fruit kernels, 551
Coumermycin A_1—absorption, oral administration, 1246
—biopharmaceutical characteristics, 1249
—pharmacokinetic profile, 309
Countercurrent distribution—analysis, 1783
Covalent addition—bisulfite ion to pyrimidinium ions, 1295
Critical micelle concentration determination—conductivity, surface-tension methods, 1433
micelle concentration—SK&F 33134-A, 1357
surface-tension values—tablet surface characterization, 1787
Croton oil–air—granuloma pouch formation, 267
Crude coal tar—analysis, 830
Crystal dissolution inhibition—water-soluble dye, 56
growth rates—single crystal method, 638
growth, sulfathiazole—mechanism, polyvinylpyrrolidone inhibition, 633
pseudopolymorphism — cephaloglycin, cephalexin, 1809
Cyano compounds, NMR—solvent effects, 1186
Cyanocobalamin-^{57}Co—formulation distribution, 254
***N*-(1-Cyclohexenecarbonyl)tryptamine** double - bond binding — hydroxyindole-*o*-methyltransferase, 573
Cyclohexene—*N*-chlorosaccharin addition, 429
Cyclopentolate HCl—pKa determination, 1559
Cytochrome P-450, alkaloid synthesis—*Claviceps purpurea*, 1149
Cytosine nucleosides—deamination, 28
Cytotoxic, antimicrobial activity—1,3-distyryl-4,6-dinitrobenzenes, 1356
Cytotoxicity—imidazole derivatives, 724

D

Datura powder—extraction of atropine, scopolamine, comparison, evaluation of methods, 1680
Decomposition, corticosteroids—C_{17} side-chain oxidation determination, 1152
products—aspirin, 1053
Defective tablets, proportion—determination, 1653
Defects, tablets and capsules—visual determination method, 1364
Degradation, clindamycin—kinetics, mechanism, product identity, 63
drug—kinetic salt effect, 1140
polypeptide, Edman—automated, 1655
products presence—isoproterenol determination, 241
rates—chloramphenicol, 464
Staphylococcus aureus RNA—temperature effect, 180
Demethylated methocarbamol derivatives—synthesis, structure determination, 1043
6-Demethylgriseofulvin metabolite—griseofulvin absorption parameters, man, 595
Dependence studies—morphine pellet formulation, 426
Deoxycholic acid effect—volume of distribution, 1423
Dermal toxicity—MBR 3092-42, 188
Deuterated benzylpenicillin—biosynthesis, 1456
Deuteriopenicillin—synthesis, 1727
Deuterium oxide effect—*Penicillium chrysogenum* penicillin production, 419
Dexamethasone, betamethasone—distinction, determination, 1045
Dextromethorphan—sustained-action suspension, 776
Dextrose, lactose beadlets—spray-dried, anhydrous lactose comparison, 1336
Diagram—automated analyzer, individual tablets, 248
—automated system, phenmetrazine HCl analysis, 1833
—automated tablet-coating system, 1171
—bead polymerization apparatus, 614
—dissolution apparatus, 692
—pellet coating equipment with monitor, 1174
—permeation cell, 610
—powder dissolution apparatus, 979
—pressure attachment, rheometer, 1012
***N,N*-Dialkylamino-1,2,3-triazoles** — synthesis, 1694
Dialkyltriazenoimidazoles—analysis, 708
Dialysis, dynamic—protein binding, 33
dynamic—protein binding determination, 39
equilibrium—albumin binding, 1563
kinetics—nicotinic acid *N*-methyl iodide, 197
—methapyrilene–polymer, binding determination, 1131
2,4-Diamino-6-hydroxy-5-arylazopyrimidines—synthesis, potential antineoplastics, 1691
1,5-Diaryl-Δ^2-1,2,3-triazolines — herbicidal activity, 1190
α-Diazoamidines—synthesis, 1694
Dibutyl phthalate—internal standard, 107
Dicloxacillin—respiratory tract, effects, 1198
Dielectric requirement—barbiturates, 1306
2-Diethylaminoethyl-*cis*-, *trans*-methylcyclohexanecarboxylic esters—synthesis, anticancer activity, 871
Di(2-ethylhexyl)phosphoric acid extraction method—isoproterenol determination, 241
Diethylphthalate transport—hexadecane–gelatin–water interface, 232
Differential nonaqueous titration—analysis, 90
permeability coefficients—double-layer, films, 1412
scanning calorimetry—identification, 1290
scanning calorimetry—identity, 785
thermal analysis—identity, 972
titration, nonaqueous—analysis, 92
Diffuse reflectance spectroscopy—analysis, 1122, 1234, 1286
—solid–solid interaction analysis, 1261
Diffusion cells—fat transfer, 1439
coefficient—testosterone, 995
Digitoxin—automated fluorometric method, tablets, 697
digoxin cyclic ketals, acetals—synthesis, 412
1,2- and 1,3-Diglycerides—determination, 840
Digoxin—automated fluorometric method, tablets, 697
Dihydroergocristine, interacting—xanthine analogs, 384
Dihydroergotoxine – xanthines — interactions, 215
Dihydromorphine, metabolites—determination, biological samples, 380
***N*-(1,1-dihydroperfluorooctyl)pyridinium** trifluoromethanesulfonate (MBR 3092-42)—synthesis, 188
Dihydrostreptomycin pamoic acid salt—synthesis, 1689
Dihydroxyacetone—synthesis of monohexanoate, -propionate, -benzoate esters, 1503
1,8-*versus* 1,5-Dihydroxyanthraquinone—effect on gastrointestinal tract, rabbit, 1518
3β,17α-Dihydroxy-6α-methylpregn-4-en-20-one 17-acetate, 3-phosphate degradation—kinetics, mechanism, 1612
Dimethoate—toxicity study, rats, 1098
1-(3,4-Dimethoxyphenyl)-2-propanol—effect on conditioned avoidance response, rat, 1842
***erythro*-α,β-Dimethylacetylcholine** iodides—structure determinations, 1118
***threo*-α,β-Dimethylacetylcholine** iodides—structure determination, 1118
5-Dimethylaminonaphthalene-1-sulfonyl Cl–chlorpromazine metabolites reaction—fluorescence, 1745
1,3-Dimethyl-5-arylhydrazonoalloxans—synthesis, potential antineoplastics, 1691
Dimethyl sulfoxide effect—hemolytic activity, antimicrobial preservatives, 478
effect—salicylate absorption, hydrophilic ointment, 1616
retention—erythrocytes, 618
1-(2,4-Dinitrophenyl)-3,5-diphenyl-4-arylazopyrazoles—synthesis, potential hypoglycemics, 876
Dioscorea tissue cultures—diosgenin determination, 864
Diosgenin, presence—tissue cultures, determination, 864
1,3,2-Dioxaphosphorinane 2-oxides—synthesis, 861
Diphenhydramine cream—analysis, 1470
Diphenylhydantoin — radioresistance enhancement, mice, 1178
1,2-Diphenylindolizine—Mannich bases, synthesis, 275, 721
Disintegration, capsules—lubricant, filler effects, 169
Dissociation, thermal—tolbutamide in alcohols, polyethylene glycol 400, 1663
Dissociation-constant determination—methodology, 700
Dissolution—aminoalicyclic penicillin, anhydrous, dihydrate, 1265
apparatus, comparison, evaluation—capsule dosage forms, 989
apparatus—design, evaluation, 692
behavior—commercial tablets converted to capsules, 1034
behavior—poorly water-soluble drugs, 606
in vitro—SETD–wax compressed tablets, 511
rates—aspirin dosage forms, 1792
rates, behavior—single crystals, compressed disks, 56
rates—effect of starch, 1034
rates—griseofulvin dosage forms, 937
rates—pentaerythritol tetranitrate tablets, 273
rate—surfactant effect, 579
solubility rates—SK&F 30097, 1290
test apparatus—diagram, 947
Distribution characteristics—cyanocobalamin-^{57}Co in tablets, 254
—coumermycin A_1, 1249
metabolism, excretion—perphenazine dimethiodide-^{14}C, 976
metabolism, whole body retention—TIBA, carboxyl-^{14}C-labeled, 257
methotrexate—mice, 149
1,3-Distyryl-4,6-dinitrobenzenes—synthesis, 1356
Disulfiram—chronic feeding studies, rats, 1267
1-(Dithioacetic acid)-pyridinium betaines—synthesis, 114
Dithizone—metal-ion interference elimination, 835
***O,O*-Ditrimethyl** siloxy chloramphenicol diastereomers—structure confirmation, effect of pyridine, acetonitrile, 501
Diumycin—intermolecular bonding, 749
Diuretic activity—ethacrynic acid analog, 869
Dosage forms, *p*-aminosalicylic acid and salts—analysis, 683
Dose dependence—sulfanilamide half-life 1845
relation, toxogonin—plasma blood levels, 793

Dose-dependent elimination kinetics, apparent—experimental artifact consideration, 1847
Double-layer films—permeability, relationship of water vapor, humidity, 1344
—theoretical considerations, 1412
Drug absorption—aspirin, derivatives, rectum, dog, 1353
buccal—clindamycin, 873
—intestinal, 154
intestinal—mesenteric blood flow effect, 878
—membrane storage effect, 72
metabolism—intestinal, 164
passive—model membranes, 1759
transport, gastrointestinal tract—theoretical models, equations derived, 651
transport—theoretical model, 644
Drug administration rate—plasma concentration plateau, 1423
concentration time integral—central compartment, 722
content uniformity, mean potency estimations—tablets, 210
content variation—sugar coating, tablets, 553
crystal dissolution—inhibition, 56
effect—bead polymer formation, 614
entrapment, molecular scale—controlled-release method, 1578
entrapment, molecular scale—release-rate control, 1581
product design—mathematical optimization techniques, 1587
release, controlled—polymeric matrices, 1131
release, controlled—through polymeric films, 610
tolerance—pentobarbital, rats, 1020
Drug-metal-ion adjuvants, drug–metal chelates—diffuse reflectance comparison, 1286
Drug-receptor theory—adrenergic drugs, 1205
Drugs, absorption—polysorbate 80, oleic acid, effects, rate intestine, 874
Dye effects—optical rotatory dispersion, 431
Dyes, organic—first pKa determination, 1683
thymoleptics—thermodynamics, bovine serum binding, 1563
yellow—separation, identification, 266

E

Echinococcus granulosus scolices—cholesterol biosynthesis, 676
E. coli generation rates—spectinomycin concentration, 760
Editorials
Advancing the Cause of Therapeutic Orphans (September)
AFPE and the "Funding Crunch" (October)
Clinical Evidence—In 1970 Terms (August)
Communicating Scientific Information (February)
Contemporary Education in Pharmacy (July)
Environment is Our Concern, Too (April)
"Pollution of the Printed Word" (November)
Quo Vadis, USP? (June)
Too Isolated and Aloof (December)
Toward Total Involvement (March)
Why the Decline in NDA'S? (May)
Zero Tolerance Revisited (January)
Elastomeric matrix—ethanol separation, determination, 1184
Electrically produced seizures—convulsive threshold, 950
Electrolyte effect—diethylphthalate transport, hexadecane–gelatin–water interface, 232
HCl concentration effects—methyl salicylate and benzoate solubility, 1625
pH effects—apparent partition coefficients, phenothiazines, 1281
polysorbate 80, concentration effects—interphase transport, 659
solutions—oil droplets, adsorbed surface-active ion interaction, 1125
Electrolyte-concentration effect—cholestyramine binding, 788
Electron microscopy—erythrocyte lesion determination, 618
Electrophoresis—separation monitoring, 1420
Electrophoretic mobility—cholesterol particles, 601
Electrostatic methods—microencapsulation of aerosols, 1367
Elimination half-life, riboflavin—age effect, 487
Emetic agents—centrally acting, 823
Emetine HCl injection—analysis, 1649
Emission spectrograph, direct—analysis, 1200
Emulsions, effect—preservatives, 372
—hexadecane–water–polysorbate 80, 744
—particle collision probability, 1125
—phase equilibria effect, 1001
Energy change—aqueous–lipid partitioning, 1376
Enzymatic degradation—plasmalogens, 283
Enzyme active sites—catalytic peptide, 129
inhibitory activity—hydrophobic interactions, drugs, 865
4-Epianhydrotetracycline determination—tetracycline products, 1160
Epidermal surface colloids—acid–base binding properties, 1461
Epidermis, mouse—3-methylcholanthrene, benzene, 1093
Epimerization, tetracyclines—reaction products separation, identification, 224
Epitetracycline—analysis, separation in tetracycline, 558
Equations—dosage numbers/subcutaneous area for asymptotic minimum level, 714
—doses, dosing intervals, calculation, 1796
—tablet drug uniformity, mean potency, 210
Equilenin solution—internal standard, 535
Equilibrium conditions, model compartments—thermodynamic activity, drugs, 1376
dialysis—bovine serum albumin salicylate binding, 1047
dialysis—copolymer–*p*-toluene sulfonic acid sodium interaction, 751
Ergosterol—19-norsteroid synthesis, 449
Ergot alkaloid production—shake cultures, 702
–xanthine complexes—solubility effect, 1673
Ergot alkaloids, congeners—ionization constants, determination, 700
derivatives—complexes, methysergide, caffeine, 1836
derivatives—complex formation, 215
—physicochemical analyses, 384
Erythrina suberosa seeds—phytochemistry, chemical constituents, 1179
Erythrocyte hemolysis—dimethyl sulfoxide induced, 618
protection, hemolysis—dimethyl sulfoxide, 478
Erythrocytes, behavior—water–tetramethylurea system, 1243
Erythromycin effect—*Escherichia coli* steady-state growth, 1448
Ester degradation determination—polycarboxylic acid interference, 130
Estrogens, free—quantitative separation, 1483
Estrone dermatological products—analysis, 535
Ethacrynic acid cyclic analog—synthesis, 869
Ethanol content, coal tar solution—determination, 830
traces—separation, determination, elastomeric matrix, GLC 1184
Ethyl acetate hydrolysis—nonisothermal stability methodology, 333
diphenamate—synthesis, 1844
Ethylene–maleic acid copolymer—dissolution, 947
oxide penetration—silicone lubricant, 717
Everted intestinal sacs—experimental technique, 164
intestine—drug absorption, *in vitro,* 154
noneverted intestine—directional permeability constants, 590
Excretion—chromonar acid metabolite, 1313
fecal, urinary—amobarbital-^{14}C, 126
rates, apparent—D-(−)-mandelic acid and homologs, 806
Extraction constants—phenothiazines, 1281
procedure, estrone—internal–external standard ratioing technique, 535
procedure—warfarin determination in plasma, 1621

F

Fat absorption—solute fluxes, *in vitro,* 1439
Fatty acid removal, erythrocytes—dimethyl sulfoxide, 618
FD&C Blue No. 1—crystal dissolution inhibition, 56
Fermentation broths—rifamycin determination, 685
Ferric hydroxamate method—solanaceous alkaloid analysis, 1646
hydroxamic acid method—color formation, 395
Fetal blood concentration, pentobarbital—maternal blood concentration, 803
Film properties, monomolecular—cellulose acetate butyrate, cellulose acetate stearate, cellulose acetate phthalate, 1188
transmission—water vapor, 1634
Films, bentonite–cellulose—relative composition effect, 1492
cellulose acetate phthalate—compression effect, area, 1750
cholesterol—initial pressure, exposure time effects, 1807
double layer—moisture permeability, 1412
double layer—permeability, 1341
Filter paper adsorption—organic compounds, 843
Filtration rate effect—filter adsorption, 843
Flavin–inulin—clearance ratio, 765
Flocculated complex systems, polysalt—chlorpromazine-^{35}S availability, 1143
Flocculation, coagulation—suspensions, 1360
pH effect—drug binding, release, 1581
polymeric—drug-concentration effect, 1131
theory—sulfaguanidine–polysorbate 80 suspension, 1848
Flow rate effect—prednisone dissolution, 692
Fluorometry—analysis, 154, 358, 397, 570, 1313, 1483, 1569, 1648, 1745, 1824
Flurandrenolone acetonide, related steroids—separation, determination, 124
^{14}C-Flurazepam HCl metabolism—humans, dogs, 1800
Folic acid—analysis, 570
Formulas, tablet—content uniformity determination, 1653
Formulation components, effect—capsule dissolution, 169
processing effects—dissolution rates, 49
Fractional molar attraction constants—steroid solubility, 414
Fractionation—aerosols, 1488
Fracture mode, tablets—testing, 688
Fumaric acid—internal standard, 1164

G

Gastric emptying—surfactant effect, 579
function assessment—Heidelberg telemetry capsule, evaluation, 425
fundus pouch, dog—absorption, antibiotics, 960
juice, human—phenobarbital, phenacetin, prednisone tablets, dissolution, 49
lesion production—acetylsalicylate-7-^{14}C, Na, acidic compounds, 325
Gastrointestinal bleeding—aspirin-induced, local, systemic effects, 1511
tract, rabbit—effects 1,8- *versus* 1,5-dihydroxyanthraquinone, 1518
Gelatin capsule size effect—aspirin release rates, 1430
Gel stability—anion concentration data, acid reactivity kinetics, 317
Genetic predisposition effect—pharmacological tests, 969
variation, solanaceae alkaloidal phenotypes—equations, phenotypic scale diagram, 1670
Genins, acylated—*G. sylvestre* gymnemic acids, 629
GLC—analysis, 63, 77, 87, 107, 201, 238, 270, 306, 400, 495, 535, 538, 561, 595, 782, 806, 823, 830, 873, 998, 1157, 1488, 1651, 1775
—analysis, separation, 501
—determination, 864
hyoscyamine, scopolamine, quantitative—tetraphenylethylene, internal standard, 1508
—identity, 629, 676, 1201
—separation, 851
—separation, determination, 1184
Glucuronic acid-salicylamide conjugation—concentration effect, 154

Glycerides—water determination, 109
Glycerol guaiacolate dosage forms—analysis, 238
Glycidic hydrazides, amides—synthesis, 942
Granuloma formation—retinyl derivatives, effects, 1195
pouch test procedure—topical steroid activity, 267
Grasshopper mouse—aggressive behavior, 969
Gravimetric analysis—iron, 1328
Grignard reaction—synthesis, 1038
Grinding, crimping effect—sulfathiazole crystals, 785
Griseofulvin absorption parameters—urinary excretion data, man, 595
dosage forms, oral—absorption, dogs, 937
—slow, rapid i.v. infusion, 53
Group protection, amino acids—peptide synthesis, 1
Growth, skeletal—index, radioiodinated tetracycline, 468
Guaiacol glyceryl ether—GLC determination, in blood, 1346
glycerol ether mononicotinate—biopharmaceutical studies, 1742
***Gymnema sylvestre* leaves**—acylated genins, isolation, 629
—constituents, 622
Gymnemic acids—isolation characterization, 622

H

Half-life, apparent—chlorphentermine, 306
Hallucinogens, mescaline—acute *versus* prolonged effects on growth, histamine stress resistance, 1659
Heidelberg FM-transmitting capsule—evaluation, 425
Hemodialysis—riboflavin elimination, 566
Hemolysis, erythrocytes—water–tetramethylurea system, 1234
Herbicidal activity—1,5-diaryl-Δ^2 1,2,3-triazolines, arylidene anilines, 1190
Hexachlorophene, dichlorophene activity, potentiation—organomercurials, 262
interaction—human epidermis, 1461
Hexadecane–gelatin–water matrix—organic solute transport, 659
1-^{14}C-*n*-Hexadecane–mineral oil–mannide monooleate emulsion—distribution, 1084
3-*O*-(*n*-Hexyl)adenine derivatives—synthesis, isolation, 344
Hippocampal stimulation—bipolar electrodes, 950
Hippuric acid, benzoic acid, *N*-γ-phenylpropyl-*N*-benzloxyamine, carbon dioxide—W-1372-^{14}C metabolites, 680
Histamine tolerance, mice—effect of mescaline HCl, 1659
Histamine-, barium chloride-, acetylcholine-induced bronchospasm—ampicillin effect, 556
Histidine decarboxylase inhibition—*p*-nitrobenxyloxyamine HCl, 1752
L-Histidyl-glycyl-L-aspartyl-L-seryl-L-phenylalanine—synthesis, catalytic properties, 129
Homatropine methylbromide analysis—reaction mechanism, 417
Human serum albumin, heat-microaggregated—structure, physical constants, 854
Humidity effect—acetaminophen stability, 193
Hydrazides, glycidic—synthesis, 942
Hydrazines—synthesis, 105
2-Hydrazino-5-nitropyridines—synthesis, 101
Hydrogenation, isoquinolinium salts—temperature, pressure effect, 998
Hydrogen, lipid–lipid hydrophobic bonding—diumycin, 749
Hydrolysis, aspirin—mechanism, kinetics, pH effect, 1053
—kinetic salt effect, 1140
mechanism—ring-substituted aziridine derivatives, 1079
pilocarpine—hydrogen-ion catalyzed, 1300
rate constants—procaine, derivatives, in lyotropic mesophases, 459
rates—acetaminophen prodrug esters, 1738
rates, enzymatic, nonenzymatic—β-methylcholine esters, 1107
Hydrolytic activity, *E. granulosus* scolices—4-^{14}C-cholesteryl acetate, 676
oxidation—rifamycin determination, 685
Hydrophilic chain length, polyoxyethylene stearates—barbiturates solubilization, 1402
Hydrophobic character relationship, adsorbate—cholestyramine binding, 329
interactions, drugs—enzyme inhibitory activity, 865
Hydrous aluminum oxide—antacid properties, preparation, 317
conversion—kinetics, 376
Hydroxamate assay procedure—polycarboxylic buffer interference, 130
5-Hydroxy-2-alkylisoquinolinium salts—hydrogenation, 998
***p*-Hydroxybenzoic acid** ester—capran polyamide film, sorption, 264
esters activity—partitioning, molecular interaction, effects, 372
23-Hydroxycholesterols, epimeric—synthesis, 719
***N*-(2-Hydroxyethyl)-diphenimide** synthesis—literature correction, 1844
Hydroxylamine HCl, ferric chloride—color formation, chloramphenicol, 1331
3-(3-Hydroxy-3-methylbutylamino)-5-methyl-*as*-, triazino[5,6-*b*]indole (SK&F 30097)—identification, 1290
Hyoscyamine, atropine, scopolamine, phenobarbital tablets, elixirs—analysis, 87
—simultaneous GLC quantification with scopolamine using tetraphenylethylene as internal standard, 1508
Hypertensive activity—hydrazidines, 105
Hypochlorite solution—*N*-chlorosaccharin degradation, 955
Hypocholesteremic activity—*N*-aralkyl-piperidyl carbanilates, 303
Hypotensive action, *dl*-, *d*-propranolol—intraventricular injection, 1276
Hypothermia, mice—sodium nitroprusside, oxotremorine induced, 1814

I

Imidazole derivatives—synthesis, 724
Imidazo(4,5-*d*)pyridazines — pharmacological screening, 1584
Imipramine-^{14}C metabolism—vehicle effect, 1780
Immunochemical properties—linear sequential polypeptide, 1849
Impurities—filters, 843
Indicators, acid-base—first pKa determination, 1683
Inhibition analysis—radioactive content method, 410
determination—dialysis cell, 372
Inhibitor potency assay—apomorphine-induced pecking syndrome, 1757
Inhibitors—α-chymotrypsin, 731
Insect repellents, dermophilic, long-lasting—dihydroxyacetone monohexanoate, -propionate, -benzoate, -undecanoate esters, evaluation, 1503
Insulin, sterility—membrane filtration, 1022
Interaction energies—computer prediction, 521
Interfacial barrier limited transport—interphase, 744
polymerization—microencapsulation, 1367
Interference—corticosteroid analysis, 1152
Interfering substances—salicylic acid determination, 397
Internal standard, "extracted"—homatropine, 87
Interphase transport—interfacial barriers, 659
Intestinal absorption, *in vitro*—quaternary ammonium compounds, 197
drug transfer—*in vitro, in situ* preparations, 72
loop, cannulated—drug absorption, *in vivo*, 154
loop—*in vivo* experimental technique, 164
Inverse isotope dilution—analysis, 680
In vitro assay—physostigmine degradation products activity, 118
studies—drug effects, peripheral nervous system, 133
In vivo studies—drug effects, peripheral nervous system, 133
In vivo–in vitro correlations, "absorption rate constants"—calculation method effect, 1049
release rates correlation—pentaerythritol tetranitrate tablets, 273
release rates—drug from capsules, 1430
Iodobismuthate complex stabilization—homatropine methylbromide analysis, 417
Iodometric titration—analysis, 955
Ion electrodes, specific—output potential measurement, 1530
Ion-exchange chromatography—separation, 481
Ionic chloride determination—analysis, 1829
nonionic materials effect—RNA degradation, 180
strength effect—high ionic concentrations, 1140
Ionizable diffusates–complexing agents—membrane permeation, 77
Ionization effect—drug permeability coefficient ratios, 590
micelles—pK value effect, 798
IR spectrophotometry—analysis, 121, 422
—glycoside structure, 622
—identity, 67, 110, 193, 276, 344, 491, 680, 719, 723, 782, 785, 823, 942, 955, 972, 1079, 1114, 1179, 1405, 1515, 1529, 1727, 1752
—identity, structure, 98, 429, 501, 1031, 1501
—structure, 114, 259, 271, 348, 427, 449, 526, 551, 563, 573, 629, 998, 1137, 1157, 1201, 1383, 1456, 1521, 1524, 1608, 1732, 1850
—structure, analysis, 861, 1191
Iron in dosage forms—analysis, 1328
Irradiation, mice—enhancement of lifespan, diphenylhydantoin effect, 1178
Irritation, sensitivity testing—MBR 3092-42, 188
Isoniazid interaction—magnesium oxide, lactose, 1234
Na, *p*-aminosalicylate mixture—analysis, 90, 92
1-Isopropyl-7-methyl-4-phenylquinazolin-2-(1*H*)-one—dissolution, 606
Isoproterenol dosage forms—analysis, 241
sulfonic acid formed in products—analysis, 241
Isotonic coefficients—tetramethylurea–water systems, 1234
IV infusion, Ciba 31-531 Ba—renal effects, 183

J

K

Ketobemidone HCl, 3,4,5-trimethoxyphenyl analogs—synthesis, 1521
Khellin—colorimetric determination, *m*-dinitrobenzene, 1025
Kinetic salt effect—pharmaceutical solutions, 1140
studies—riboflavin degradation, 297
Kinetic equations—coumermycin A_1 absorption, elimination, 309
—dialysis, small molecules, 39
—first-order model system, 403
—flexible nonisothermal stability studies, 333
—slow i.v. infusion, 53
—suspension sedimentation, 666
—two-compartment open model, 364
—urinary excretion parameters relationship, gastrointestinal absorption, 487
Kinetics—benzyl alcohol, subcutaneous absorption, 714
—cytosine nucleosides deamination, 28
—drug absorption, transport, 651
—erythromycin action on *E. coli*, 1448
mechanism—spectinomycin activity, 760
—pilocarpine hydrolysis, 1300
sedimentation, flocculated suspensions—critical height, equations derived, 671

L

^{14}C-Labeling—specific activity, 1,1-bis(*p*-chlorophenyl)-2-nitropropane, 1019
Lactose (beadlets), dextrose, evaluation—direct compression, 1336
Lactose–isoniazid systems—browning rates, 1234
Lagrangian method—optimization, drug design, 1587
Lakes, water-soluble dyes—titanium dioxide adsorbate, 1016
Latentiation, dihydrostreptomycin—by pamoate formation, 1689
LD_{50}—dimethoate, 1098

Lidocaine—*trans*-configuration, 1524
Lincomycin growth, Phase I—erythromycin effect, 1448
Lincomycin 2-PO_4—hydrolysis kinetics, 175
Linear free-energy relationships—alkaline hydrolysis rate prediction, 779
Lipid biochemistry—*E. granulosus* scolices, 676
phase polarity effect—salicylic acid transport, 314
spherules, chromate leakage—photosensitizing properties, phenothiazines, 856
Liquid crystalline phase—emulsions, 1001
scintillation spectrometry—specific activity, 1019

M

Macromolecular dissolution—temperature of product formation effect, 1526
substances—cholesterol solubility effect, 1362
Magnesium oxide, chemisorption—isoniazid, 1234
Mandelic acid optical isomers—elimination kinetics, 1775
D-(−)-Mandelic acid and homologs—mutual inhibition of urinary excretion, 806
homologs—urinary excretion, 813
Mannich base—decomposition kinetics, 1770
Mannich bases—synthesis, 275, 721
Mannich reaction—synthesis, 1038
UL-^{14}C-Mannide-labeled mannide monooleate—metabolic fate, 1088
Manometric determination—penicillinase, 81
Mass spectroscopy—identity, 63, 67, 342, 561, 1045, 1179, 1529, 1612
—structure, 551, 1696, 1732
—structure, identification, 501
Matrix boundary diffusion layer model—equations derived, 353
layer—solute uptake, 659
Maximal overlap areas, estimated—complexes, 1271
Mechanism—dimethyl sulfoxide-induced hemolysis, 618
Media additives, effect—penicillin production, 419
Medroxyprogesterone acetate release rate, *in vitro*—physicochemical factors, 353
Mefruside—effects on renal hemodynamics, 1841
Melphalan and dosage forms—analysis, 561
Melting range—sulfathiazole Form I crystals, 785
Membrane filtration—sterility testing, insulin zinc suspensions, 1022
nonporous—natural membrane components, 1759
permeation, organic molecules—molecular interaction effect, 77
permeation—surfactant effect, 579
storage effect—drug absorption kinetics, 72
Mepazine and promethazine ^{14}C-methiodides—synthesis, 772
Meperidine HCl, 3,4,5,-trimethoxyphenyl analogs—synthesis, 1521
Mescaline, asarone trimethoxyphenyl derivatives—synthesis, 1042
—behavioral effects, 1699
Mescaline HCl—effect on histamine tolerance, mice, 1659
Mesenteric blood flow—drug absorption, 878
Mestranol bulk drug—analysis, 1821
determination—tablets, 1648
Metabolic fate—mannide monooleate in mineral oil emulsion, 1088
Metabolism, central effects—stereoselectivity, 1205
—mandelic acid optical isomers, 1775
—mescaline, 1699
—plasmalogens, related derivatives, 283
—serotonin-^{14}C, imipramine-^{14}C, 1780
Metabolite, chromonar—*in vitro, in vivo* determination, 1313
Metabolites, chlorpromazine—quantitative determination, 1745
flurazepam HCl—isolation, identification, 1800
prazepam—isolation, identification, 322
—TIBA, carboxyl-^{14}C-labeled, 257
Metachromasia—molecular binding, 431
Metal ions–tetracyclines, –methantheline bromide, –bishydroxycoumarin—interactions, 1261
Metal–thiouracil complexes—structure, 1383
Metaperiodate sodium method—isoproterenol determination, 241
α-Methacrylic acid, concentration effect—release rates, polymer beads, 1398
Methallibure—determination, 835
Methanol, dioxane, sucrose, urea effects—methylene blue adsorption, 1466
Methocarbamol metabolites—synthesis, structure determination, 1043
Methotrexate pharmacokinetics—model, 149
3-(4-*o*-Methoxyphenyl-1-piperazinyl)-4′-morpholinopropiophenone dihydrochloride—elimination reaction, 1770
***N*-Methyl,** *o*-alkyl derivatives—monoamine oxidase inhibition *in vitro*, 410
3-Methylcholanthrene, benzene effects—epidermal net charge density, 1093
β-Methylcholine esters—synthesis, 1107
***cis*-, *trans*-Methylcyclohexanecarboxylic acids**—synthesis, 871
***N*-Methyl-3,4-dimethoxy-β-phenethylamine**—isolation from *Ariocarpus fissuratus*, 1840
Methylene blue—potato starch adsorption, 1466
***N*-Methyl-2-phenylsuccinimide** derivatives—synthesis, 1137
***N*-Methyl-2-phenyl-2(*tert*-aminoalkyl)-succinimides**—inhibition, butyrylcholinesterase, 1028
2-[*N*-methyl-piperidyl-(4)]-3-amino-5(4′-pyridyl)pyrazole HCl (Ciba 31-531 Ba)—renal effects, 183
***N*-Methyl-3-piperidyl-(*N′N′*)-diphenylcarbamate**—morphine (N-$^{14}CH_3$) interaction, 1783
Methylprednisolone crystals—growth rate, 638
Methyl salicylate and benzoate solubility—urea–water mixture, 1625
Methysergide maleate, caffeine complexes—interactions in aqueous solutions, effect on dissolution, partition rates, 1836
Mevalonate-2-^{14}C incorporation—cholesterol, 303

Micellar properties, nonionic surfactants—pH effect, 387
solubilization—barbiturates, 1402
solubilization, benzoic acid in cetomacrogol 1000—quantitative determination, 1427
solubilization—5,5-disubstituted barbituric acid derivatives, 220
solutions—extrinsic optical activity, 1525
Micelle formation, effect—optical rotatory dispersion, β-D-octyl glucoside, 1513
Michaelis constants—β-methylcholine esters, 1107
Microbiological activity—triazenoimidazoles, 1533
analysis—coumermycin A_1, 1246, 1249
analysis—erythromycin action on *E. coli*, 1448
analysis—plasma, antibiotic concentration, 960
test method—analysis, 1255
Microelectrophoresis—cholesterol–bile salts, surfactant interactions, 601
Microencapsulation—review, 1367
Microirradiation—riboflavin, quantum efficiency, 297
Micronization effect—poorly water-soluble drug, 606
Microorganisms—mechanism, kinetics, drug activity, 760
Mineral oil—metabolic fate, 1084
Mineral oil–mannide monooleate emulsion—subcutaneous, intramuscular injection, 1088
Model, kinetic—polyvinylpyrrolidone effect, sulfathiazole crystal growth, 633
methotrexate distribution—one, two compartments plus gut lumen, 149
three-phase—drug absorption kinetics, 72
two-compartment open—coumermycin A_1, 309
two-compartment, open—pharmacokinetic parameters, 364
two-phase compartment—theoretical investigation, 644
Models, compartment—formulation, computation, 403
Moisture analysis—tablet-coating rate control, 1171
concentration—ascorbic acid stability, 229
Molar absorptivity—Na hypochlorite, chloramine, 1168
Molecular association—barbital–caffeine 2:1 crystalline complex, 1666
interaction, aqueous solutions—structural similarity effect, 1597
orbital conformation, oxotremorine—muscarinic activity, 112
sieve technique—solubilization study, 1427
weight—diumycin, 749
Molecules, organic—dimethyl polysiloxane membrane permeation, 77
Monitoring system, electronic—pecking syndrome, pigeons, 1757
Monoamine oxidase inhibition—imidazo-(4,5-*d*)pyridazines, 1584
inhibition *in vitro*—phenethanolamine derivatives, 410
inhibitors—synthesis, 1445
Morphine (N-$^{14}CH_3$) extraction enhancement—*N*-methyl-3-piperidyl-(*N′N′*)-diphenylcarbamate, 1783
implantation pellet, formulation—tolerance, physical dependence studies, 426
metabolites—determination, biological samples, 380
Multiple regression analysis—use, misuse, 1496
Muscarinic receptors—3-trimethylammoniumtetrahydrofuran halides, 4-substituted, synthesis, pharmacologic testing, 1676
Mycophenolic acid, related compounds—determination, 1157
Mydriatics—corneal absorption reinforcement, 1559

N

Near IR spectrophotometry—analysis, 109
Nervous system, peripheral—test methods, drug effects, 133
Neutron-activation analysis—aluminum, 1005
Nicotine analogs, pyrrolidine substituted—synthesis, 342
Nitrobenzamide, *N*-cyclohexyl—synthesis, *N*-alkyl, *N*-aryl, *N*-aralkyl analogs; evaluation, CNS depressant activity, 1838
Nitrobenzene detection—benzaldehyde, 1008
4-(4-Nitrobenzyl)pyridine alkylation—4-{*p*-[(2-chloroethyl)-(2-hydroxyethyl)-amino]-phenyl}butyric acid, 563
Nitrofurazone effect—vaginal odors, 495
Nitrogen dioxide, concentration effect—cholesterol film interaction, 1807
Nitroimidazoles, *N*-1-substituted—determination in blood, urine, 201
Nitrone—synthesis, reactions, 342
***p*-Nitrophenol-2,6-^{14}C** urinary metabolites—determination, 1528
β-Nitrostyrene derivatives—antimicrobial activity, 1185
NMR spectra—solvent effects, cyano compounds, 1186
NMR spectroscopy—analysis, 840, 1164, 1182, 1574, 1809, 1821
—glycosidic structure, 622
—identity, 67, 387, 449, 823, 851, 972, 1079, 1529, 1612, 1727
—molecular interaction, 281
—structure, 98, 271, 342, 427, 551, 563, 573, 1137, 1157, 1445, 1521, 1524, 1608, 1685, 1696, 1732, 1770, 1844
—structure, analysis, 1042
—structure, identification, 429, 501, 1043
Nonionic surfactant—micellar properties, pH effect, 387
surfactants—dermatitic effect, rabbits, 858
Norepinephrine stores, relationship—acetylcholine tachyphylaxis, 1252
Nornuciferine derivatives—synthesis, 823
19-Norsteroids, unnatural configuration—synthesis, 449
Nucleic acid synthesis inhibition—5-substituted pyrimidine-6-carboxaldehydes, 1637
Nucleosides, sugar moiety substituted—synthesis, isolation, separation, 344
Nylon microcapsules—release rate, preparation, 338

O

Observational studies, animals—drug effect, peripheral nervous system, 133
***n*-Octacosane**—internal standard, 400
β-D-Octyl glucoside—optical rotatory dispersion, micelle formation effect, 1513
Odors, vaginal—threshold, intensity determination, 495

Oil droplets, electrostatic interaction—adsorbed surface-active ions, 1125
Ointment bases—salicylic acid, 985
Oleaginous products—aluminum determination, 1005
1-^{14}C-Oleate-labeled mannide monooleate—metabolic fate, 1088
Oleic acid, polysorbate 80—drug absorption rate, rat intestine, effects, 874
Optical density—microbial culture concentration, 262
—*S. aureus* growth determination, 81
Optical rotation—identity, 551
Optical rotatory dispersion-circular dichroism—molecular binding determination, 431
—identity, 427, 449
β-D-octyl glucoside—micelle formation effect, 1513
Optimum tablet design—techniques, 1587
Oral dosage form design effect—dissolution rates, 827
ORD—identity, 806
Organic solute binding specificity—aqueous solution, 1601
species, small—interaction, 1103
Ouabain cyclic ketals, acetals—synthesis, 412
Oxotremorine—molecular orbital conformation, 112
sodium nitroprusside-induced hypothermia—autonomic drugs effect, 1814
Oxygen consumption—disulfiram effect, 1267
nitrogen pattern, interatomic distances—antileukemic activity, 1630
sampling, analysis—void volumes, ampuls, vials, 94

P

Pamoate formation—role in dihydrostreptomycin latentiation, 1689
Paper chromatography—analysis, identity, 468
—autoradiographic analysis, 1780
electrophoresis—identity, 129
—identity, 629, 723, 1420
—radio scanning, 976
—separation, 772
—separation, identification, 551, 1528
Paper disks—microbe-inhibition analysis, 1185
Parabens—mutual solubilizing potential, 1574
—NMR analysis, 1182
Parenterals, agricultural premixes—*d*-biotin analysis, 400
Particle-size determination—bead polymers, 614
distribution—emulsions, 744
effect—drug release from polymer–drug flocculates, 1578
effect—phenobarbital dissolution, 49
effect—powder dissolution, 979
Partition coefficient, apparent—phenothiazines, 1281
cholesterol—hexadecane–polysorbate 80 system, 744
correlation—Hansch's π-, Hammett's constants, Bondi's group contribution surface area, 197
—silicone, medroxyprogesterone acetate, 353
Partition coefficients—quaternized amines, 278
salicyclic acid—oil–water phases, 314
Partitioning rate—dihydroergocristine–xanthine complex, 384
dihydroergotoxine—xanthine effect, 215
Pecking syndrome, pigeons—chlorpromazine HCl, methdilazine HCl inhibition, 1757
Pectin, acacia, dextrans effect—cholesterol solubility, 1362
Pellets, poorly water-soluble drug—dissolution, 606
Pellotine, racemic—synthesis, 271
Penicillin, aminoalicyclic (Wy-4508)—anhydrous, dihydrate forms, solubility, 1265
blood levels—dogs, 1255
penicilloic acid in urine—penicilloic acid determination, 757
production, *P. chrysogenum*—deuterium oxide effect, 419
Penicillinase production—*Staphylococcus aureus*, 81
Penicillin G, potassium, stability—alcoholic solution, 726
Penicillium chrysogenum cultures—benzylpencillin deuteration, 1456
Pentacyanoamine ferroate—color reagent, 1008
Pentaerythritol tetranitrate sustained-release tablets—drug release, 273
Pentobarbital, labeled—fetal blood, 803
—tolerance development, rats, 1020
Pentylenetetrazol-10-^{14}C—absorption, excretion, 1409
Peptides, linear—synthesis trends, 1
Perchloric acid, acetous—titrant, 90
—titrant, 92
Percutaneous absorption—salicylate in hydrophilic ointment, 1616
Perfused intestine—drug transport, 590
Permeability coefficients, interfacial barriers—surfactant, electrolyte type, concentration effect, 232
coefficient—polymeric films, 610
constants, directional—ratios, 590
two-sided—double-layer films, 1344
Permeation half-lives, apparent—small molecules, 33
water vapor—double-layer films, 1341
Perphenazine dimethiodide-^{14}C—synthesis, 976
Pesticide toxicity study—rats, 1098
Peyote constituents—chemistry, 1699
pH binding profile, small molecule—kinetics, 39
effect—chlorpromazine-^{35}S–polysalt complex stability, 1143
effect—clindamycin stability, 63
effect—lincomycin-, clindamycin 2-PO_4 hydrolysis rates, 175
effect—mydriatic activity, 1559
effect—oxidized folic acid fluorescence, 570
effect—salicylate absorption from hydrophilic ointments, 1616
effects—cellulose acetate phthalate monolayers, 1750
ionic strength effects—chloramphenicol release, polymer beads, 1398
meter, expanded scale—ion electrode potential output determination, 1530
organism population, nutrient concentration, effects—spectinomycin-affected generation rates, 760
precipitation effect—hydrous aluminum oxide, chemical and physical properties, 317
temperature effects—allylic phosphate hydrolysis, 1612
pH-mobility profiles—cholesterol dispersions, 601
Pharmaceutical applications—microcapsules, 1367
sciences—1969 literature review of pharmaceutics, 883
Pharmacokinetic constants determination—post-infusion curves, 53
equations—methotrexate absorption, distribution, excretion, 149
parameters—chlorphentermine distribution, elimination, 306
Pharmacokinetics—phenylbutazone potentiation, warfarin activity, 1258
—riboflavin renal clearance, 765
trimethoprim—man, dog, 358
Pharmacological screening—6-acetoxy-2-methylisoquinuclidine methiodides, 98
—antiradiation compounds, 114
—2-diethylaminoethyl-*cis*-, *trans*-methylcyclohexanecarboxylic esters, 871
—glycidic hydrazines, amides, 942
—4-thiazolylmethoxyureas, 276
Pharmacological test methods—drug activity, peripheral nervous system, 133
Pharmacology—pyrrolidine-substituted nicotine analogs, 342
Pharmacopeias, dosage form uniformity testing—comparison, 530
Pharmacy, general—dosage forms, stability, technology, 883
Phase equilibria—w/o emulsions, 1001
separation—microencapsulation, 1367
solubility—molecular interactions, 1597
Phenazine–alkylxanthines, benzene derivatives—interaction, 1597
Phenmetrazine HCl tablets—analysis, 1833
Phenol red absorption, rat—sodium deoxycholate effect, 705
Phenothiazine derivatives—surface activity, oil–water partitioning—dodecane, *n*-octanol, 1281
Phenothiazines—photosensitizing properties, 856
Phenotypes, alkaloidal, in Solanaceae—heredity, environmental influences, 1670
Phenoxyethyl penicilloic acid—determination in urine, 757
Phenoxymethyl penicilloic acid—determination in urine, 757
Phenylbutazone effect, warfarin activity—pharmacokinetics, 1258
***N* - Phenyl - *N′* - 2(4 - phenyl - 5 - arylazothiazolyl)thiocarbamides**—synthesis, 348
Phenylpropanolamine, glyceryl guaiacolate, chlorpheniramine, dextromethorphan—simultaneous determination, 538
***N*-γ-Phenylpropyl-*N*-benzyloxy acetamide** (W-1372)—metabolism, 680
Phosphate, inorganic—analysis, 1433
Phospholipid composition, rabbits—normal, surfactant-treated skin, 858
Phosphoric acid effect—reserpine–vanadium pentoxide fluorogen, 1824
Photosensitizing properties—phenothiazines, 856
Physical aspects—pharmaceutics, 883
properties, tablets—lactose beadlets, spray-dried, anhydrous lactose, dextrose, 1336
Physiochemical constants, enzyme inhibition—correlation, 865
Physiological availability—griseofulvin, man, 595
Physiologic surfactants—gastrointestinal drug absorption, 579
Physostigmine—degradation products, 118
Pigment formation—*P. atrotomentosus* cultures, 1420
Pilocarpine in aqueous solution—hydrolysis, 1300
solutions—analysis, 395
pKa determination, first—acid-base indicators, 1683
Placental transfer, rat—pentobarbital, metabolites, 803
Plasma, analysis—chlorphenesin, 107
concentration—experimental blank errors, 1847
half-life—toxogonin, 793
levels—antibiotics, 960
levels—chlordiazepoxide and metabolites, 1569
levels—^{14}C-flurazepam, 1800
protein binding—methotrexate, 149
protein–drugs—interactions, 1563
Plasmalogens, related derivatives—chemistry, metabolism, review, 283
Plateau principle—plasma drug concentration, 1423
Polarcrilin potassium—interaction, amine drugs, 481
Polarimetry—analysis, 333, 1525
—identity, 344, 449, 806
—pilocarpine cyclization, 1300
Polarity, barbiturates—activity correlation, 1306
Polarography—analysis, 201
Polyamide–silica gel chromatography—analysis, 266
Polyethylene glycol 6000 effect—griseofulvin absorption, 937
Polyethylene glycol–water system—paraben solubility, 1574
Polyethylene maleic anhydride–phenylpropanolamine interaction temperature—effect on dissolution rate, 1526
Polymer beads—chloramphenicol release, 1398
monolayers—as model for enteric, film coatings, 1188
Polymer–drug interaction—drug salt form effect, 1578
Polymeric films—drug permeability, 610
flocculation—cationic drug entrapment, 1131
unplasticized films—water vapor transmission, 1634
Polymerization process—sustained-release dosage form, 614
Polymorphic forms—sulfanilamide-d_4, 972
hydrated forms, SK&F 30097—determination, 1290
Polypeptide—automated synthesis, degradation, 1655
Polypeptides—known amino acid sequence, 724
linear sequential—synthesis, 1849
Polysorbate 20 effect—polymeric film formation, 610

Polysorbate 80, oleic acid—drug absorption rate, effects, rat intestine, 874
Polysorbates, barbiturate solubilization—hydrophobic chain length effect, 220
Polytetrafluoroethylene coating—suppository mold, 848
Poly(L - tyrosyl - L - glutamyl - L - alanyl-glycyl)-glycine-1-^{14}C ethyl ester—synthesis, 1849
Polyvinylpyrrolidone molecular weight effect—sulfathiazole crystal growth, 633
Porphyrins, ferric ions, disodium versenate, effect—penicillinase production, 81
Potassium permanganate effect—folic acid fluorescence, 570
tablets—analysis, 1482
Potentiation, stereoselective—adrenergic drugs, 1205
Potentiometric nonaqueous titration—analysis, 708
titration—analysis, 683, 1383, 1649, 1819, 1821
titration—monomeric, micellar acylcarnitines, 798
Powder beds—liquid penetration rate, 169
blends flowability, lot variability effects—capsule weight variation, 547
Powders, slightly soluble—dissolution, sink conditions, 979
Pramoxine—GLC internal standard, 538
Prazepam-^{14}C metabolites—urinary excretion, dog, 322
Prednisone absorption enhancement—*N,N*-di-*n*-propylpropionamide, 575
—dissolution rate profile, 692
Pressure attachment, rheometer—design, evaluation, 1012
Probenecid effect—mandelic acid optical isomers elimination, 1775
effect—riboflavin distribution, elimination, 566
effects—riboflavin, renal clearance, plasma protein binding, 473
Procaine amide activity—amide reversal, *ortho*-methylation, effects, 1405
penicillin—analysis, medicated feeds, 568
quaternary derivatives, hydrolysis—lyotropic smectic mesophases, 459
Process analysis—mathematical optimization techniques, 1587
Promazine, chlorpromazine, triflupromazine ^{14}C-methiodides—synthesis, 1114
Propellent, formulation effects—aerosol dosage weight, 1488
d-**Propoxyphene HCl**—hydrophobic self-association, 281
dl-, *d*-**Propranolol**—central hypotensive activity, 1276
Protein binding—competitive inhibition, drugs, 39
binding determination—cellophane membrane, dialysis, 33
incorporation—tryptophan and analogs, 702
synthesis inhibition—5-substituted pyrimidine-6-carboxaldehydes, 1637
Protein-deficiency effect—dimethoate toxicity, 1098
Proteins, human, bovine plasma—imipramine, desipramine, 3-chlorodesmethylimipramine, interaction, binding, model, 1505
Proton magnetic resonance—analysis, structure, 1456
Psychotomimetic agents—3,4-dimethoxyamphetamine oxygen analog, pharmacological screening, 1842
Pyridylethane derivatives (methiodide salts)—synthesis, 710
Pyrimidine-6-carboxaldehydes, 5-substituted—synthesis, 1637

Q

Quantum efficiency, riboflavin—equations derived, 297
Quaternary ammonium alkylsulfates—apparent partition coefficients, 197
Quinidine, quinine effect—RNA, DNA, protein, lipid synthesis, 704
Quinine, quinidine effect—*Tetrahymena pyriformis*, 704

R

Radiation protection—diphenylhydantoin effect, mice, 1178
Radioactive labeling—codeine, morphine, dihydromorphine, metabolites, 380
solute—fat transfer, diffusion cells, 1439
Radioactivity accumulation—labeled mineral oil injection, monkeys, rats, 1084
Radiochromatography—analysis, 1114
—purity determination, 772
Radioprotective agents—aminoethanethiols, aminoethanethiol *S*-sulfonic acids, *N*-substituted, 1350
Rate constants—anion adsorption, cholestyramine, 788
—double-exponential curve fitting, 514
Reactivators—organophosphorus - inhibited acetylcholinesterase, 710
Rechromatography procedure—separation, identification, 1528
Reciprocal rate plots, vapor transmission theoretical justification, 1634
Rectal absorption, dog—aspirin, derivatives, 1353
Redispersibility—sulfaguanidine suspension, 518
Refractive index—crystal axes determination, 638
—determination, 387
Refractometry, differential—diffusion rates, 1439
immersion—polymer determination, 947
Regression analysis—α-chymotrypsin structure–activity relationship, 731
—factors affecting blood pressure lowering, 1110
Release rate—sodium pentobarbital nylon microcapsules, 338
—chlorpromazine-^{35}S–polysalt complex, 1143
—drugs in polymeric matrices, 1131
in vivo, in vitro—polymer-bound drug, 1581
—salicylic acid, ointment bases, 985
Release-rate stability—dextromethorphan suspension, 776
Renal dynamics—mefruside, effects, 1841
infusion—Ciba 31-531 Ba, 183
tubular reabsorption, secretion—riboflavin, 765
Reproduction, longevity, body weight—disulfiram effects, 1267
Repulsive interaction—flat plates, spheres, 1125
Reserpine and derivatives in tablets—determination, 1824
effect—acetylcholine, tyramine activity, 1252
Reserpine-induced hypothermia—imidazo-(4,5-*d*)pyridazine blocking effect, 1584
Respiratory ventilation—ampicillin effect, 556
^{47}Ca retention—chronic corticoid administration, 368
Retinoic acid, topical application—inhibition of wound-healing retardation of anti-inflammatory agents, 1036
Retinyl compounds, activity—structural relationship, 851
—effect on granuloma formation, 1195
Reverse phase chromatography—separation, 622
Reversibility—erythromycin antimicrobial activity, 1448
Review Articles
α-Chymotrypsin: A Case Study of Substituent Constants and Regression Analysis in Enzymic Structure–Activity Relationships, 731
Determination of the Decomposition of Aspirin, 1053
Mechanisms of Surfactant Effects on Drug Absorption, 579
Microencapsulation, 1367
Peyote Constituents: Chemistry, Biogenesis, and Biological Effects, 1699
Pharmaceutical Sciences—1969: Literature Review of Pharmaceutics, 883
Pharmacological Testing Methods for Drugs Acting on the Peripheral Nervous System, 133
Plasmalogens and Related Derivatives: Their Chemistry and Metabolism, 283
Recent Trends in the Synthesis of Linear Peptides, 1
Small Molecule–Macromolecule Interactions as Studied by Optical Rotatory Dispersion–Circular Dichroism, 431
Steric Aspects of Adrenergic Drugs, 1205
Syntheses and Biological Activity of 5-Aminoimidazoles and 5-Triazenoimidazoles, 1533
Rheological behavior, bentonite–cellulose suspensions—relative composition effect, 1492
Rheometer—chemical balance use, 1764
rotational—aerosol rheological properties, 1012
Riboflavin absorption—intestinal, 487
distribution, elimination—anephric patients, 566
photochemistry—additives, temperature, pH effects, 297
renal clearance, man—probenecid effect, 473
—saturable renal tubular reabsorption, 765
Ribonucleic acid (RNA) degradation, leakage—thermally induced, 180
Rifamycins, dosage forms—differential determination, 685
Rotating-bottle apparatus—dissolution testing, 827
Rotating-flask method—dissolution—rate determination, 1792

S

Salicylamide—absorption, accumulation, metabolism, 154
glucuronide formation, transport—intestinal, 164
Salicylate absorption—hydrophilic ointment, 1616
binding—bovine serum albumin, 1047
concentration levels—rate constants, curve fitting, example, 514
metabolites—separation, determination, 270
Salicylate–glycerol guaiacolate dosage forms—analysis, 238
Salicylates, wound-healing mechanism—analogy to other anti-inflammatory agents, 1036
Salicylic acid determination—aspirin dosage form, buffered, unbuffered, 397
in ointment—release, uptake, permeation, 985
—*in vitro* transport kinetics, 314
Sample size effect—prednisone dissolution, 692
Sampling device, void volume oxygen—diagram, 94
Schulman cell, evaluation—transport studies, 314
Scintillation counting, whole body—analysis, 468
Scintillometry—analysis, 126, 254, 322, 368, 414, 676, 803, 1084, 1114, 1143, 1362, 1409, 1439, 1780, 1783, 1800
—analysis, ^{32}P-incorporation, 858
liquid—analysis, 380
Scopolamine, atropine dosage forms, analysis—collaborative study, 1324
atropine, extraction from *Datura* powder—comparison, evaluation of various procedures, 1680
—simultaneous GLC quantification with hyoscyamine using tetraphenylethylene as internal standard, 1508
Sedimentation coefficients—diumycin, 749
height—sulfaguanidine–polysorbate 80 suspension, 1848
kinetics—flocculated suspensions, 666
kinetics—flocculated suspensions, equations, 671
volume—sulfaguanidine suspension, 518
Serotonin-^{14}C metabolism—vehicle effect, 1780
Sex effect, dogs—penicillin blood levels, 1255
time of year effects—blood pressure lowering, drugs, 1110
Side effects—toxogonin, 793
Silica gel effect—ascorbic acid stability, bioavailability, 229
Silicic acid–adsorbed ascorbic acid—stability, 1122
Silicone lubricant effect—ethylene oxide bactericidal action, 717
rubber matrix—medroxyprogesterone acetate release, 352
rubber membrane—salicylic acid transfer, 985
Small molecule binding—protein, 39
Small molecule–macromolecule interactions—review, 431

Sodium deoxycholate—effect of phenol red absorption, rat, 705
Sodium hypochlorite determination—aqueous solutions, 1168
Sodium pentobarbital—microcapsule preparation, polymerization, 338
Solanaceae biovariation—selecting for alkaloidal phenotypes, effects of heredity, environment, 1670
Solanaceous alkaloids with degradation products—analysis, 1646
Solid–solid interaction—determination, 1261
interactions—diffuse reflectance spectroscopy, 1286
Solids processor—preparation, tablet granulations, 540
Solubility, aqueous—thiouracils, 1383
drug—surfactant effect, 579
organic compounds—filter adsorption, 843
ratios—barbiturates, ethanol–water systems, 1306
—solute interaction effect, 1601
Solubilization, barbiturates—polyoxyethylene stearates, 1402
testosterone—surfactants, 995
Solute–urea interaction effect—solubility, 1695
Solutes, small organic—binding tendency classification, 1601
Solvent contamination, trace—determination, 117
effect—small organic species interaction, 1103
effects—NMR spectra, cyano compounds, 1186
evaporation rate—effect on film, 1341
Solvolysis, corticosteroid-21-PO_4 esters—pH profile, activation energy, aggregation effect, 1433
Spectinomycin action, *E. coli*—kinetics, mechanism, 760
Spectral changes, drugs—metal-ion adjuvants, 1286
Spectrophotometric analysis—organic solutes, 1601
Spectrophotometry—analysis, 297, 473, 558, 856, 858, 1673
UV, visual—analysis, 1427
Spot testing—nitrobenzene in benzaldehyde, 1008
Spray-congealed coating—dextromethorphan crystals, 776
formulations—SETD–wax compressed tablets, 511
Spray drying—titanium dioxide lake preparation, 1016
Spray-drying effect—poorly water-soluble drug, 606
Sputum—rheological measurements, 1764

Stability—alcoholic potassium penicillin G solution, 726
ascorbic acid—humidity, excipient effects, 229
—aspirin and dosage forms, 1053
—clindamycin aqueous solutions, 63
constants, complexes—solvent composition effect, 1103
constants—organic molecular complexes, 1271
constants—solute binding, 1601
coumermycin A_1—gastrointestinal tract, 1246
emulsions—emulsifier concentration, 1001
—lincomycin-, clindamycin 2-PO_4 aqueous solutions, 175
studies—flexible, nonisothermal, 333
sulfaguanidine suspension—electrolyte, surfactant, vehicle effects, 518
suspension—theory, experimental findings, 521
—vitamin A α,α-dimethylpalmitate, 121

Starch—effect on dissolution, 1034
potato—methylene blue adsorption, 1466
Starch–iodine spray—TLC spot identification, 757
Stereoselectivity in biosynthesis—uptake, binding, release, 1205
Sterically hindered vitamin A esters, 121
Sterility testing—insulin, membrane filtration, 1022
Steroid hormones—solubilization, aqueous solutions, bile salts, 1499
solubility—estimation, 414
Steroids—absorption, 575
anti-inflammatory—topical activity determination, 267
—antimineralocorticoid, catatoxic effects, independence, 712

Stirring rate effect—capsule dissolution, 989
—crystal growth, 638
—drug binding, 1581
Stress, hindleg ligation—amobarbital-^{14}C metabolism, 126
sound induced—seizures, 1046
Structural similarity, antileukemic agents—triangular pattern, nitrogen, oxygen atoms, 1630
studies—*T. crebriflora* alkaloids, 1608
Structure, phenothiazines—surface activity relationship, 819
Structure–activity relationship—α-chymotrypsin substituent constants, 731
—monoamine oxidase inhibitors, 1445
Structure–activity relationships, drugs—optimal structure prediction, 1376
—mescaline derivatives, 1699
—precautions concerning interpretation, 1496
—procaine amide derivatives, 1405
Structure–excretion rate relationship—D-(−)-mandelic, DL-tropic acids, 813
1 - Styryl - 3,4 - dihydroisoquinolines—synthesis, 576
***N*-Substituted** cyclohexylamines—synthesis from 1,2-diphenylindolizine, 721
Substrates—α-chymotrypsin, 731
Sucrose effect—methylene blue visible spectrum, 1466
inversion—nonisothermal stability methodology, 333
Sulfacetamide formulation—sulfanilamide determination, 240
Sulfaethidole—betaine-induced optical activity, 1525
half-life—mesenteric blood flow, 878
Sulfaethylthiadiazole–wax tablets—drug release, 511
Sulfaguanidine suspension—physical stability, 518
Sulfamethazine—analysis, medicated feeds, 568
***p*-Sulfamoylphenylazo** compounds, substituted—antimalarial properties evaluated, 1031
Sulfanilamide—capacity-limited biotransformation, 1845
—sulfacetamide degradation product, 240
Sulfanilamide-d_4—polymorphism, 972
Sulfathiazole crystal growth—polyvinylpyrrolidone effect, 633
crystals—growth rate, 638
species—Form I, 785
Sulfisoxazole—slow, rapid i.v. infusion, 53
Sulfonamides—absorption, diffusion data, rats, 651
Sulfonylureas—thermal dissociation in alcohols, polyethylene glycol 400, 1663
Suppositories, absorption—aspirin, derivatives, dog, 1353
rectal—content uniformity, 1319
Suppository molds—suppository releasing agent, 848
Surface activity, phenothiazines—chemical modification effect, 819
potential—acylcarnitine micelles, 798
pressure—cellulose acetate phthalate monolayers, 1750
pressure measurements—solvent contamination determination, 117
tension method—pH effect, micelle concentration, 387
tension values–affinity constants, correlation—bile salts, 329
Surface-to-volume ratio, stirring—salicylic acid transport, 314
Surfactant concentration effect—prednisone dissolution, 692
effect—antibiotic absorption, 960
effect—aspirin dissolution from dosage forms, 1792
effect—diethylphthalate transport, hexadecane–gelatin–water interface, 232
effect, drug absorption—mechanism, 579
effect—SETD release, tablets, 511
Surfactants effect—testosterone transport, cellulose membrane, 995
Suspension—triglyceride fatty acid-coated dextromethorphan salt, 776
Suspensions, flocculated—sedimentation cakes, 666
flocculated—sedimentation kinetics, equations, 671
pharmaceutical—aggregation mechanism, 1360
pharmaceutical—stability, 521
Sustained action—dextromethorphan suspension, 776
Sustained-release dosage form—bead polymerization, 614
products—multiple-dose therapy, 1796
Synthesis—dihydroxyacetone monohexanoate, -propionate, -benzoate esters, insect-repellent activity, 1503

T

Tablet coatings—drug content variation, 553
content uniformity—determination, 1653
dissolution rates—human gastric juice, 49
granulations, preparation—solids processor, 540
strength determination—diametral-compression test, 688
surfaces—characterization, 1787
Tablet-coating system—self-programming, automated, 1171
Tablets, capsules—relative defect determination, 1364
direct compression—lactose beadlets, dextrose anhydrous, spray-dried lactose, 1336
ethylene–maleic acid copolymer—dissolution study, 947
individual—automated analysis, 248
—mean potency, content uniformity, 210
optimization design—phenylpropanolamine HCl, 1587
sustained-, nonsustained-release—pentylenetetrazol-10-^{14}C, 1409
Telemicroscopy—liquid, tablet surface contact-angle measurement, 1787
Temperature effect—aminoalicyclic penicillin solubility, 1265
effect—clindamycin stability, 63
effect—oxidized folic acid fluorescence, 570
of preparation, polymer–drug system—physicochemical properties, 1526
stirring, pH-buffer concentration effect—dialysis rate, 33
Tensile strength, tablets—measurements, 688
Teratogenicity—audiogenic stress effects, albino mice, 1661
Tertiary bases—synthesis, 278
Testosterone derivatives—solubilizing effect of sodium cholate, deoxycholate, 1499
transport—cellulose membrane, 995
Tetracycline mixture—anhydrotetracycline, 4-epianhydrotetracycline, tetracycline, 4-epitetracycline determination, 1480
^{131}I-Tetracycline—skeletal growth index, whole body measurements, 468
Tetracyclines, degradation products—identification, 224
methantheline bromide, bishydroxycoumarin—metal-ion interactions, 1261
Tetrahydrofuran—9-chloroacridine solvent, 838
Tetramethylpyrimidopteridinetetrone – alkylxanthines, benzene derivatives—interaction, 1597
Tetramethylurea–sodium chloride system—erythrocyte hemolysis, 1234
Tetraphenylethylene, chloroform dissolved—internal standard, 1157
internal standard—quantitative GLC of hyoscyamine, scopolamine, 1508
Tetronic acids, diphenyl substituted—*Paxillus atrotomentosus* cultures, 1420
Theoretical approach—noncumulative blood levels, sustained-release therapy, 1796
considerations—data fitting, models, 403
models—drug absorption, transport, gastrointestinal tract, 651
Thermal analysis, differential—dextromethorphan salt, 776
patterns—pellet coating, 1174
stability—ascorbic acid, 1122
stability—statistical techniques for prediction, equations derived, 464
Thermodynamic analysis—structure–activity relationships, 1376
properties—anhydrous, dihydrate aminoalicyclic penicillin, 1265
Thermodynamics—drugs–albumin binding, 1563
4-Thiazolylmethoxyureas—synthesis, 276
Thick-layer chromatography—separation, identification, 257
1 - Thiocarbamoyl - 3 - methyl - 4 - arylhydrazono - 2 - pyrazolin - 5 - ones—synthesis, 348
Thiophene derivatives, benzene analogs—dipole moment, structure determination, 1685

Thiopseudoureas—in formation of 2-amino-2-oxazoline, 1515
Thiouracils–metals—complexation, 1383
Thymidine-, uracil-, amino acids-^{14}C—*Tetrahymena pyriformis* utilization, 704
Thymoleptics, dyes—bovine albumin binding, 1563
tricyclic—binding to human, bovine plasma proteins, 1505
Tissue/plasma ratios—methotrexate, 149
Titanium dioxide lakes—preparation, 1016
Titration, aqueous—dissociation-constant determination, 700
—iron analysis, 1328
potentiometric, nonaqueous—analysis, 1271
pH-stat—pilocarpine degradation determination, 1300
Titrimetry—analysis, 1649
TLC—analysis, 193, 201, 241, 325, 558, 697, 757, 823, 858, 1008, 1019, 1028, 1084, 1122, 1783
—analysis, radioactivity, 803
—identity, 629, 680, 723, 782, 1042, 1088, 1179
paper chromatography—separation, identification, 412
—separation, 491, 568, 622, 676, 864, 1157, 1476, 1569, 1770, 1800, 1821, 1829
—separation, determination, 1025
—separation, identity, 67, 124, 224, 322, 563, 1612, 1663, 1745
—warfarin determination in plasma, 1621
Tolbutamide in biological fluids—determination, 782
—thermal dissociation in alcohols, polyethylene glycol 400, 1663
Tolerance, pentobarbital—rats, 1020
(+) - *trans* - 2 - *o* - Tolylcyclohexanol—configuration confirmation, X-ray crystallography, 1675
Toxic effects, rats—dimethoate, 1098
Toxogonin, intramuscular injection—oxime blood levels, 793
Tranquilizer, antidepressant effects—learned, unlearned behavior, 964
Transfer, standard free energy—solute in urea solution, water, 1695
Transport, interphase—interfacial barriers, 232
rates—drugs through model membranes, 1759
system—D-(−)-mandelic acid, DL-tropic acid excretion, 813
Triazenoimidazoles—synthesis, stability, 1533
Trifluoperazine tablets—analyses, 391
Triflupromazine, chlorpromazine, promazine ^{14}C-methiodides—synthesis, 1114
2,3,5-Triiodobenzoic acid (TIBA), carboxyl-^{14}C-labeled—metabolic fate, 257
Trimethoprim—pharmacokinetic profile, 358
3-Trimethylammoniumtetrahydrofuran halides, 4-substituted muscarinic receptors, synthesis, pharmacologic testing, 1676
Trimethylsilyl ether derivative—6-demethylgriseofulvin, griseofulvin metabolite, 595
DL-**Tropic Acid,** D-(−)-mandelic acid—competitive inhibition, urinary excretion, 813
Tryptophan, 5-methyltryptophan effect, alkaloid production—comparison, 702
^{14}C-L-Tryptophan, tryptophan analogs—cytochrome P-450, 1149
Tumor aerobic respiration inhibition—5-substituted pyrimidine-6-carboxaldehydes, 1637
Turbidimetric analysis—biological potency, 1160
assay—deuteriopenicillin antimicrobial activity, 1727
Turbidity method—pH effect, micelle concentration, 387
Tylophora crebriflora—separation, isolation, physical properties, six alkaloids, 1501

U

Ultracentrifugation—sedimentation coefficients, 854
Ultrafiltration—phenol red–methylcellulose interaction determination, 33
Uniformity specifications—coefficient of variation calculations, 530
Urea aqueous solution—salt effects, 1625
effect—alkyl copolymer binding sulfonate ions, 751
effect—*d*-propoxyphene HCl self-association, 281
Urea–water systems—solubilization mechanism, 1695
Urinary excretion—griseofulvin metabolites, 937
excretion—D-(−)-mandelic acid and homologs, 806
excretion—toxogonin, 793
excretion—chlordiazepoxide and metabolites, 1569
fecal excretion—^{14}C-flurazepam, 1800
UV—rate of formation, 429
UV light—TLC spot visualization 224, 1008
UV spectrophotometric, fluorometric, colorimetric analyses, mestranol—comparison, 1648
UV spectrophotometry—analysis, 28, 33, 39, 77, 87, 121, 126, 180, 201, 220, 241, 248, 329, 338, 391, 478, 568, 610, 618, 827, 835, 976, 979, 985, 989, 1025, 1160, 1168, 1470, 1472, 1476, 1483, 1499, 1563, 1574, 1597, 1621, 1625, 1663, 1738, 1800, 1809, 1829, 1833
—glycosidic structure, 622
—analysis, identity, 468, 481
—identity, 67, 110, 193, 240, 344, 412, 751, 772, 869, 955, 1114, 1529
—identification, structure, 1031
—reaction monitoring, 779
—solubilizate location, homogeneous gels, 459
—structure, 259, 1383, 1445, 1608, 1732, 1850
—structure, analysis, 1042
—structure, identification, 501 1501

V

Vacuum tumble dryers—data, mixing, drying, formulation, processing factors, 540
Vaginal odor theshold, intensity—analysis, 495
Vanadium pentoxide–reserpine reaction—fluorescence, 1824
Van Urk's reagent—color formation, 1010
Vapor phase chromatography—analysis, 998
—determination, 353
Vapor phase osmometry—complex formation data, methysergide maleate, caffeine, 1836
Variability determination—dosage form units, 530
drug content—suppositories, 1319
Vasoconstrictive activity—hydrazidines, 105
Veratrum viride alkaloids—bioassay, 1110
Vials—oxygen determination, 94
Vinylpyridine–vinylpyrrolidone copolymers—synthesis, 751
Viscosity effect—dialytic rate, 33
effect—suspension cake concentrations, 666
measurements—viscosimeter, chemical balance comparison, 1764
Viscosity-increasing additives—aerosol foam effect, 1012
Visnagin—colorimetric determination, *m*-dinitrobenzene, 1025
Vitamin A α,α-dimethylpalmitate—synthesis, 121
Volatile coating solutions—application monitoring, 1174
Volume of distribution—plasma concentration plateau, 1423

W

Warfarin activity—phenylbutazone effect, 1258
plasma determination—method comparison, 1621
Water concentration, vapor pressure—films, 1412
determination—trace amounts, 109
vapor—transmission through films, 1634
Wax matrix effect—SETD release, tablets, 511
Weight variation—clomacran PO_4, 547
Wet granulation, direct compression—cyanocobalamin-^{57}Co distribution comparison, 254
Wound healing—mechanism of action, retinyl derivatives, 1195
—retinyl compound effect, 851

X

Xanthine–dihydroergocristine complex formation—solubility effect, 384
Xanthine–ergot alkaloid complexes—solubility effect, 1673
Xanthines effect—dihydroergotoxine dissolution, 215
X-ray crystallography—configuration, (+)-*trans*-2-*o*-tolylcyclohexanol, 1675
—structure determination, 1118
X-ray diffraction—analysis, 317
—barbital–caffeine 2:1 crystalline structure, determination, 1666
—identity, 376, 414, 1290
—polymer–drug flocculates, 1578
X-ray diffractometry—identity, 785
X-ray powder diffraction—analysis, 1809

Y

Yellow dyes—analysis, 266

Z